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1 Executive Summary 
 
 
Part 1 
This document makes recommendations for establishing cut-off levels for drugs in per se legislation 
for driving under the influence. It does not have the ambition to write a model per se drug-driving le-
galisation, but based on the authors’ experience, the experience in member states and Norway, the 
results of DRUID and scientific literature, it aims at giving pertinent considerations when a nation 
wants to determine per se cut-off levels. 
 
Most European countries adhere to one of two possible approaches or definitions of the act of drug 
driving: 11 countries use the impairment approach, 8 countries use zero-tolerance or per se limits and 
9 countries combine these two approaches into a two-tier system. 
 
Until now, all countries that have per se legislation use analytical cut-offs, i.e. the lower concentrations 
that can reliably be determined by forensic laboratories. In some countries, these are the lowest limits 
of quantitation of the forensic laboratories, in other countries, they have been established by experts. 
In some countries, even if they are called analytical cut-offs, some consideration was given to a rela-
tionship with effects, e.g. by measuring only the active cannabis component THC, instead of the inac-
tive metabolite, and using a cut-off that corresponds to a concentration after a single dose, when the 
drug still has effects. 
 
There are three classes of substance thresholds: “Risk thresholds”: concentrations in blood that indi-
cate a certain accident risk or impaired driving. “Lower effect limits”: the lowest concentration where an 
effect on driving is observed. And “Limit of detection”:
In establishing thresholds, one must realise that the relationship between the concentration and the 
effect is not linear for most drugs, and that a given concentration could correspond to low effects (e.g. 
in a tolerant individual) or high effects (e.g. in a drug-naive subject). 
 based on technical limitations in order to guar-
antee a valid and reliable analytical result and avoid false positive results. 
 
The list of drugs to be included in per se legislation will depend on the situation in each country, e.g. 
the drugs that are most often found in the driving population or in drivers involved in an accident. Most 
countries have a very limited list of 10 substances or less. There is a consensus on not including me-
dicinal drugs in the list. It is not reasonable to define cut-off values for patients in long-term treatment. 
Even high doses may lead to fewer effects because of tolerance. 
 
Norway and the Netherlands recently tried to determine safe driving limits and they arrived to very 
similar values, e.g. 3 ng/mL THC or 48 and 50 ng/mL for MDMA in whole blood. Norway defined a risk 
threshold for THC, where the impairment is comparable to 0.05% BAC. 
 
In determining “lower effect limits”, stimulant drugs like amphetamines and cocaine pose a particular 
challenge. The correlation between drug concentration and risk of traffic accidents/impairment is vari-
able or insufficiently documented. In experimental studies, at the (rather low) doses that were given, 
driving performance increases rather than decreases. However, in epidemiological studies indications 
of increased accident risk could be found. Since the available literature regarding the central stimu-
lants did not provide evidence for dose-response effects, limits for graded sanctions were not sug-
gested. Experimental and epidemiological results should be interpreted together for the determination 
of cut-offs. 
Usually, inactive metabolites are not included in the legislation, except when the parent drug is unsta-
ble and is metabolised very rapidly. 
Another issue to take into consideration is the rapid metabolism of drugs. Some drugs like THC have a 
very rapid metabolism, and if the delay between the stop or accident and the blood sampling is long, 
the concentration could have decreased markedly (based on a half-life of 1.4 hours, 3 ng/mL of THC 
decrease to 0.68 ng/mL after 3 hours). The “lower effect limits” should be established with this in mind.  
Another possibility, but less easy to implement, is that the lowest concentration that can be accurately 
measured (LOQ, limit of quantitation) is used instead of the lower effect limit when the sampling delay 
is longer than 2 or 3 hours.  
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The epidemiological studies in DRUID have shown that people very often use more than one drug. 
The question has been raised if the per se lower effect limits or the LOQ should be used when more 
than one drug (or alcohol) is detected. Some have recommended using the LOQs. 
 
One of the risks of using lower effect or safe driving limits is that inevitably questions will be raised 
with respect to the dose that can be taken still remaining under the limit. One should realize that es-
tablishment of lower effect limits does not mean that one condones drug use. Moreover, in many 
countries (e.g. Sweden and Finland), people who are sanctioned for driving under the influence of 
narcotics will also be sanctioned for drug use, or sanctioned for drug use even if inactive metabolites 
are detected. But to achieve the compliance of the population a clear legislation should be imple-
mented, which differentiates drug and traffic policy. 
 
It is not a problem to limit the list of drugs in per se legislation to a few substances, if the per se law is 
combined with an impairment law, where all other impairing substances are covered. In this scenario, 
a quick and easy to enforce procedure exists for the most common drugs, and a more elaborate pro-
cedure exists for the less frequent cases, including medicinal drugs, combination of drugs, withdrawal, 
etc. It is not realistic to develop cut-offs for all the existing medicinal and recreational drugs. Moreover 
for new drugs, it might take some time before the different cut-offs have been established. 
 
 
Part 2 
In DRUID many experimental results were gathered and a literature review was performed on conver-
sion factors between plasma and whole blood and between whole blood (B) and oral fluid (OF). 
 
The drug concentration ratios between oral fluid and blood (sometimes called oral fluid to blood con-
version factors) were studied by collecting paired samples of oral fluid and whole blood from drivers in 
Belgium, Finland, Italy and Norway. Oral fluid to blood (OF/B) concentration ratios were calculated. 
Large variations were found between individuals; typically the coefficient of variation (relative standard 
deviation) was 50 to 100%. Therefore, conversion factors cannot be used to accurately estimate drug 
concentrations in blood based on drug concentrations in oral fluid. The estimated equivalent cut-off 
concentrations for oral fluid and blood were used for the calculations of drug prevalence (Deliverable 
2.2.3) and for the odds ratio calculations (Deliverable 2.3.5) 
 
Drug analysis in samples of oral fluid can be used to estimate the drug prevalence in blood if using 
equivalent cut-off concentrations. Three formulae were used for estimating equivalent cut-off concen-
trations using the average OF/B ratio, median OF/B ratio or percentile regression. To determine which 
formulae fit the original paired data best, the prevalence of samples above selected cut-off concentra-
tions in blood was estimated using the formulae and compared with the actual prevalence in blood. 
The accuracies of the three procedures were calculated for the chosen cut-off concentrations in blood 
and for concentrations corresponding to 2.5 times and 5 times the analytical cut-off. The procedure 
with the least average percent deviation (in absolute value) from the actual number of subjects with 
drug concentrations above the cut-offs in blood was identified as the best one for each substance 
separately. Based on this ‘equivalent’ cut-offs were established for oral fluid. 
 
The use of dried blood spots (DBS) has potential as a precise and inexpensive option for the determi-
nation of several analytes in small blood samples. The small sample volume of 100 µL requires very 
sensitive techniques. By using LC-MS/MS, all analytes investigated could be determined with suffi-
cient lower limits of quantitation (LLOQs). Evaluation data showed no significant differences in preci-
sion as well as lower limits of detection (LLODs) and LLOQs. Analysis of DBS is feasible with the ad-
vent of increasingly sensitive MS technologies such as LC-MS/MS. The DBS/B ratios were very close 
to 1.00, and the relative standard deviations ≤ 8.56%. The use of DBS in routine analysis will result in 
simplified handling during blood sampling, transport and storage as well as sample processing in the 
laboratory. DBS drug analysis can be regarded as a valuable and inexpensive alternative to determi-
nation from whole blood. 
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Part 1: Per se limits 
 
2 Introduction 
 
As stated in the general conclusions of the Pompidou Group in June 2003 “The law enforcement and 
judicial authorities should have clear legislative and regulatory provisions, in line with which they can 
prosecute and convict individuals driving a vehicle whilst under the influence of psychoactive sub-
stances” (1) 
 
In case of combating driving under influence of alcohol, legislative regulations and enforcement prac-
tices are clearly defined. Further, on per se limits for alcohol are based on scientific risk research that 
is a prerequisite to assure the compliance of the population with these regulations. Determining legis-
lative regulations against drugged driving is more difficult as a variety of aspects has to be taken into 
account. First of all, one needs to determine which psychoactive substances should be prohibited from 
being consumed before driving. Of course it should be forbidden to drive under the influence of illegal 
drugs with impairing effects, but what should be recommended in case of taking prescription drugs? 
On the one hand, the impairing effects of some prescribed medicines are well known, but on the other 
hand the patient’s need for mobility should be respected. Furthermore, the disease itself may affect 
the driving behaviour even more and the use of medication could decrease this effect. Thus a balance 
between concerns about ensuring road safety and the therapeutic needs of an individual has to be 
guaranteed.  
 
The main challenge in establishing legal regulations combating drugged driving is to define clear rules 
for detecting and sanctioning a drugged driver. Regarding alcohol a clear correlation between con-
sumption, blood concentrations and the score of driving impairment is proved since several years, 
whereas up to now defining limits for combating drugged driving comprises a lot of challenges. To 
facilitate legal practice, laws against drugged driving are based on zero tolerance and consider drivers 
“impaired” if any amount of a listed drug or its metabolites can be detected in blood. But as the pro-
gressing technical improvement allows the detection of traces of substances long after they were 
taken and when the impairing effects have subsided, the need for setting lowest levels is indispensa-
ble. Therefore, use of the term “analytical threshold” for establishing substance thresholds for zero 
tolerance legislation should be revised and criteria should be established for cut-off determinations.  
 
An important aspect is the relationship with drug use and drug possession laws. In many EU coun-
tries, use of narcotic drugs is illegal, and ‘one cannot have a legal level of an illicit drug’. Having cut-
offs that are higher than the analytical cut-offs would give the impression that one is condoning nar-
cotic drug use. This has been handled differently in member states: in Belgium, the law explicitly men-
tions that the observations made for enforcing the per se law cannot be used for prosecuting other 
drug-related offences, while in Sweden, someone sanctioned for driving under the influence of nar-
cotic drugs, receives an additional sanction for drug consumption, and in Finland a finding of the can-
nabis metabolite THCCOOH in urine during the process of detecting drugged driving results in a sanc-
tion for drug use. But to increase the acceptability by the population, a clear legislation should be im-
plemented, which differentiates drug and traffic policy. 
 
 
In DRUID an expert group was established to work on these issues and in this document their recom-
mendation towards determining cut-offs for per se legislation are presented. As analytical issues like 
determining which specimen to use (blood, plasma, saliva) for substance detection are important for 
defining cut-offs, the findings of the toxicological group in DRUID are represented in chapter 0. 
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3 Objectives 
 
Besides addressing legal issues, cut-off values of psychoactive substances that can impair driving 
ability and hence present an increased risk of unsafe driving can only be established by focussing risk 
assessment based on empirical science as well as tackling analytical issues.  
 
Therefore the following chapters will cover and discuss: 
 
• Selection which scientific data are suitable for the estimation of substance related accident 
risk. 
• Discussing pros and cons of different research methods 
• Establishing a list of criteria for definition of a cut-off  
• Selection of the psychoactive substances for which cut-offs should be determined 
• Determination of substances that should be included, based on their prevalence  
• How to deal with metabolites 
• How to deal with combined consumption 
• How to deal with legal prescribed medicine use 
• Determination of analytical procedures 
• Defining the analytical substrate  
• Quality assurance of laboratory analysis 
• Determining measurement errors 
• Pros and cons of whole blood and plasma  
• Saliva (oral fluid) 
• Blood spots 
• Conversion factors between the different body fluids 
 
First of all the different legal approaches combating driving under influence and the definition in terms 
of wording for substance cut-offs are explained in the following. 
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4 Different legal approaches 
 
4.1 Introduction 
 
Most European countries adhere to one of two possible approaches or definitions of the act of drug 
driving: i.e. 1) the impairment approach (11 countries) or 2) zero-tolerance or per se limits (8 coun-
tries). Nine countries combine these two approaches and employ a two-tier system (2).  
 
Impairment approach:
 
 if the driver shows clear symptoms of impairment whether in his personal be-
haviour or its driving style, he will be prosecuted. Most EU countries use fixed protocols to prove signs 
of impairment. An overview is given in D 3.2.2. One problem is that these so called drug recognition 
expert (DRE) programs are derived mostly from alcohol impairment detection protocols and are there-
fore not usable to detect all kind of drug effects.  
Per se limits:
 
 if a drug is found in a driver’s body fluid (blood, in some countries like Belgium, France, 
Spain and most of the Australian states, oral fluid) above a defined cut-off concentration he will be 
prosecuted. This approach facilitates prosecution. But for population compliance the cut-offs should be 
based on scientific risk analysis. This per se legislation is sometimes also called ‘zero-tolerance legis-
lation’, but it is a confusing term. “Analytical thresholds” have not been defined according to technical 
issues but to drug concentrations of the active compound were an effect on driving ability might occur. 
They were often established taking the effects of the drugs into account to drug concentrations of the 
active compound were an effect on driving ability might occur. In most legislations the active ingredient 
of cannabis THC is the target drug, not the inactive THCCOOH, or setting a higher cut-off for ben-
zoylecgonine (3). 
  
Figure 1: Map of Europe showing the countries with per se (zero tolerance), impairment legislation and two-tier 
system. (2) 
Two-tier system: Per se limits (for drugs limits for zero tolerance) are combined with an impairment 
approach. This system allows combining the advantages of the two legal regulations. As research has 
up to now not proposed a clear-cut solution to link substance consumption to distinct levels of impair-
ment this two-tier system seems to be the most favourable one to combat driving under psychoactive 
influence other than alcohol. Moreover, this system allows combining a less severe sanction when 
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drugs are present above the per se limit and a more severe sanction when the driver was impaired. 
This is e.g. the case in Germany and in the proposed Norwegian per se legislation. 
The situation in the different EU countries is illustrated in Figure 1. 
 
4.2 Definition of cut-offs  
 
One may differentiate four classes of substance thresholds: 
 
“Risk thresholds”:
 
 Psychoactive substance concentrations in blood are indicating a certain accident 
risk respectively impaired driving. In DRUID Task 1.3 risk thresholds for psychoactive substances are 
determined showing the same accident risk as a blood alcohol concentration (BAC) of 0.5 g/L.  
“Lower effect limit”
 
: The cut-off has been set so that the concentration is to the lowest concentration 
where an effect on driving is observed. Substance detection below this threshold does not imply re-
cent psychoactive substance consumption or being under the influence. This limit is comparable to a 
BAC of 0.2 g/L. 
“(Lower) Limit of quantification (LLOQ or LOQ)”:
 
 the smallest measured content from which it is possi-
ble to quantify the analyte with an acceptable level of accuracy and precision. This threshold is based 
on technical limitations and should guarantee a valid and reliable analytical result, also avoiding false 
positive results.  
“(Lower) Limit of detection (LLOD or LOD)”: 
 
is the smallest measured content from which it is possible 
to deduce the presence of the analyte with reasonable statistical certainty. An alternative definition is 
that LOD is the lowest concentration of an analyte that the analytical procedure can reliably differen-
tiate from background noise or LOD is the smallest amount or concentration that can be readily distin-
guished from zero and be positively identified according to predetermined criteria and/or levels of con-
fidence (4). 
New analytical technologies are more and more sensitive and enable detecting very small quantities of 
substances. An increasing/inherent problem will be then that a positive blood sample will not always 
imply traffic safety risks i.e.: when an illicit or medicinal drug was consumed many hours or days be-
fore and psychoactive effects are no longer present. A second problem is that with continuously de-
creasing analytical thresholds, legal thresholds cannot be established. To overcome this problem, 
“lower effect limits” were proposed. This should define the cut-off value for zero-tolerance legislation, 
based on scientific knowledge about the non-impairing effect of low concentrations. Cut-offs must be 
defined below which impairment can be excluded and not for technical limits. However, low limits 
make sense, e.g. for stimulant drugs. While the DRUID on-road driving studies did not show an impair-
ing effect at therapeutic doses of stimulants; the risk increases if they are taken in combination with 
sleep loss or alcohol. Deliverables 1.1.2.b and D1.2.1 concluded that impairment may be detected 
only at very high doses, but also that the effects after an acute intoxication with amphetamines are 
frequently characterised by sleepiness and exhaustion, which are, of course, of special relevance for 
traffic safety. Some studies have shown that most accidents occur when the effect wears off and fa-
tigue sets in. Logan concluded that “methamphetamine at any concentration is likely to produce symp-
toms that are inconsistent with safe driving (5). Although the Task 1.4 expert group (of which the first 
author of this deliverable was not a member) decided not to define cut-offs for post acute effects be-
cause one may not sanction fatigue based on drug or alcohol consumption, this doesn’t change the 
fact the most countries have used low cut-offs in their legislation. 
 
When the per se legislation was introduced in Germany, the following considerations were made (3):  
“However, for the definition of the limit values these concentration ranges alone are not crucial, but 
security of the proof with consideration of disturbance is determining. If necessary the limit value 
should encompass a concentration range of the substance, with which the endangerment of traffic 
safety is usually enclosed. The proof must include the fact that the subject has consumed an impairing 
drug and that the time of consumption is sufficiently close. One must be able to quantitate the drugs at 
the limit concentrations with coefficients of variation that are representative and that have been deter-
mined by interlaboratory comparison. Values that can be determined quantitatively sufficiently exactly 
must be two standard deviations above the limit of determination. Sometimes however values can be 
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sufficient, which lie over the safe detection limit, because for individual substances individual aspects 
must be considered. (…) 
 
Because of its instability in vitro, cocaine can only rarely be detected. Even the use of preservatives 
like sodium fluoride can only partially stabilise the analyte in the blood between sampling and freezing 
in the laboratory. As a consequence, the most abundant metabolite benzoylecgonine must be deter-
mined. Since it is inactive and excreted more slowly, the limit value that can be specified will be set 
substantially higher than it would be based on the possibility to analytically determine the parent drug. 
Also in the case of heroin a determination of the originally consumed material via the parent drug or 6-
acetylmorphine is not possible so easily. However morphine, an active metabolite is available. 
 
To confirm the correctness of the findings, additional criteria can be introduced, that confirm the plau-
sibility of the result of the analysis. This can occur by means of the determination in a legally defensi-
ble way of specific metabolites and/or the exclusion of certain influence factors. Such plausibility crite-
ria do not have an influence on the height of the limit value. 
 
With all the described factors the limit values meet the quality requirements for a legally defensible 
proof. As analytical limit values they are not to be equated with an effect limit for the analytes, al-
though they cover “drug effect” prospectively. Which should be understood as “drug effect” requires if 
necessary more detailed discussion. If only whole blood is available for the determination (no serum) 
is present, other limit values or conversion factors must be specified (3)” 
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5 Overview of European regulations concerning per se legislation 
 
A DRUID questionnaire concerning legal regulations regarding drugged driving and legally defined 
cut-offs for illegal psychoactive substances was distributed in the European member states, Norway, 
Switzerland and Croatia. The reply was complemented with the official data of the EMCDDA and data 
available to the authors (see Table 1). 
 
Table 1: Legal regulations applied in each country 
Countries Legal approach related to driving 
Impairment Zero tolerance 
Austria X  
Belgium X X 
Bulgaria  X 
Croatia  X 
Cyprus X Coming soon 
Czech Republic X X 
Denmark X X 
Estonia  X 
Finland X X 
France  X 
Germany X X 
Greece X  
Hungary  X 
Ireland X  
Italy  X 
Latvia  X 
Lithuania  X 
Luxembourg X  
Norway X Coming soon 
Poland  X 
Portugal  X 
Slovakia X X 
Slovenia  X 
Spain X  
Sweden  X 
Switzerland  X 
The Netherlands X Coming soon 
United Kingdom X  
 
Four of the 17 countries defined cut-offs for illegal drugs in plasma (resp. serum), whereas all others 
defined their cut-offs in whole blood. This has to be taken into account when comparing the data of 
table 2. In some countries (e.g. France and Belgium), the cut-offs are mentioned in the law, while in 
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other countries, it is based on the recommendations of an advisory group (Germany), or the lower limit 
of quantitation of a national forensic laboratory (Sweden, Finland). 
 
Table 2: Cut-offs per substance applied in each country. Some cut-offs are defined in the law, some others are 
the ones used by the forensic laboratories 
Countries 
TH
C
 
TH
C
 
C
O
O
H
 
A
m
pheta-
m
ine 
M
etham
-
pheta-
m
ine 
M
D
M
A 
M
D
A
 
M
D
E
A 
C
ocaine 
B
enzoyl-
ecgonine 
M
orphine 
Belgium  1  25  25   25 25 10 
Denmark  1  20 20 20 20 20 20  10 
Finland* 1 5 25 25 25 25 25 10 10 2.5 
France 1  50 50 50 50 50 50  20 
Germany 1  25 25 25 25 25 10 75 10 
Great Britain  2 10 25 50 50 50 50 50 50 25 
Greece  1  25 25 25 25 25 10 10 10 
Hungary  > 0 > 0 > 0 > 0 > 0 > 0 > 0 > 0 > 0 > 0 
Ireland 2 5 10 10 10 10 10 2 10 10 
Italy*** 0 0 0 0 0 0 0 0 0 0 
Italy** 2 2 20 20 20   2  10 
Italy LOQ 0.5 0.5 20 20 20   10 10 5 
Luxembourg 2  50 50 50 50 50 50 50 20 
Poland LOQ 2 50 50 50 50 50 50 50 50 20 
Portugal 3 5 5 5 5 5 5 5 5 5 
Slovenia  0.3 5 20 50 20 50 50 10 5 50 
Sweden  LLQ LLQ LLQ LLQ LLQ LLQ LLQ LLQ LLQ LLQ 
Switzerland 
1.5 + 
30%  
15 + 
30% 
15 + 
30% 
15 + 
30%  
15 + 
30% 
15 + 
30%  15 + 30% 
      * cut-offs used by the National Institute of Public Health 
(National Institute for Health and Welfare) until the 2009  Impairment   Plasma/serum  
Zero tolerance  Whole blood  ** scientific guidelines by Forensic Toxicologists 
Both    *** by legislation 
 
 
5.1 Discussing different regulations in Norway, The Netherlands and 
Denmark 
 
Recently, three EU countries determined cut-offs for per se legislation. In this part, we review the pro-
cedures and criteria used, before we compare the cut-offs that were obtained. 
 
5.1.1 Norway 
 
Since 1936, Norway has an impairment-based law for driving under the influence (DUI) of alcohol 
(ethanol). The impairment limit for alcohol is now 0.2 g/L and graded sanctions are given for higher 
blood alcohol concentrations, with limits corresponding to levels of 0.5 g/L and 1.2 g/L. For non-
alcohol drugs Norway has an impairment-based law regarding DUI. In these cases, the judicial proc-
ess requires an expert witness statement to evaluate driver impairment and to compare the degree of 
impairment to corresponding BACs.  
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5.1.1.1 
 
A harmonisation of the system for DUI of alcohol and non-alcohol drugs in Norway 
The Norwegian Ministry of Transport and Communications sought to establish a new limit based penal 
process in DUI cases involving drugs not subject to a prescription from a physician. The new system 
should be based on a zero tolerance policy against impaired driving, disregarding individual tolerance 
and drug-disease interactions. The Ministry asked an advisory group to suggest a system for handling 
DUI of the most frequently used non-alcohol drugs that lead to increased risk of traffic accidents and 
legislative concentration limits for impairment of non-alcohol drugs corresponding to a BAC of 0.2 g/L 
(“impairment limits”) and BACs of 0.5 and 1.2 g/L (“limits for graded sanctions”). 
 
5.1.1.2 
  
Impairment limits  
This limit corresponds to the degree of impairment comparable to a BAC of 0.2 g/L. The proposed 
limits for the drugs are given in Table 3. 
This limit should represent a threshold where higher concentrations in blood are likely to induce im-
pairment comparable to those accompanying blood alcohol concentrations of 0.2 g/L.  
For alcohol a concentration of 1 g/L is assumed to lead to euphoria and impairment, and the legal limit 
for alcohol in Norway is 0.2 g/L. The low limit for alcohol is thus 1/5 of a concentration of alcohol seen 
after a typically euphoric dose. Due to lack of scientific documentation in this low concentration area, 
the group estimated 1/5 of the concentration of a “drug-dose” to find the low limits. Corrections were 
made due to factors regarding therapeutic drug concentrations, half-lives etc. 
 
5.1.1.3 
 
Limits for graded sanctions 
These limits (Table 3) correspond to the degree of driving impairment related to BAC levels of 0.5 g/L 
and 1.2 g/L respectively.  
 
 
 
Figure 2: Example of a diagram showing the correspondence between the effects of THC and ethanol. A cut-off of 
0.2 g/L ethanol corresponds to 1.3 ng/mL THC in whole blood (from Vindenes et al., manuscript in accepted for 
publication in Forensic Science International.) 
Impairment limits corresponding to the 0.5 and 1.2 g/L limit for alcohol were defined for the drugs 
where scientific evidence showed a dose-response relationship for impairment. To suggest specific 
limits for each drug, the literature has been searched to fine the “best/most relevant” publications re-
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garding traffic relevant impairment, according to certain criteria. Impairment on the tests at different 
drug concentrations was compared to alcohol impairment, and plotted in diagrams for each substance. 
From these diagrams the limits corresponding to impairment at 0.5 and 1.2 g/L alcohol were sug-
gested. 
A total of 45 studies were included. The results for each of the included drugs were plotted in separate 
diagrams. Figure 2 shows an example of such a diagram for THC. Impairment at the drug concentra-
tions tested was compared to BAC levels tested in the same study. Since a low number of doses of 
alcohol have been investigated, arrows indicate if the impairment on each test was more or less pro-
nounced than at the tested BAC. An estimated effect interval was drawn if impairment was estimated 
to be in the same range for the investigated drug concentration as for alcohol. The open circles repre-
sent the actual concentrations of the tested substances. Some of the studies conducted tests at differ-
ent time points after drug ingestion, and test results at different concentration levels were plotted in 
these instances. Some studies included various relevant psychomotor tests, and summaries of the 
impairment from these tests were plotted for each study.  
 
5.1.1.4 
 
Discussion 
Per se legislation limits have been proposed for a selection of frequently detected psychoactive drugs 
in DUI cases in Norway. Due to a lack of scientific evidence, a pragmatic approach has been used. 
The scientific literature for comparing risk of traffic accidents and reduced performance at different 
concentrations levels after ingestion of drugs and alcohol is sparse, and the suggested limits may be 
subjected to debate. Since the aim of this work was to harmonise the judicial process involving alcohol 
and non-alcoholic drugs, the working group found this method acceptable for the suggested legislative 
limits. 
 
Limits for graded sanctions were not suggested for the central stimulants, due to lack of scientific evi-
dence for the relationship between a drug concentration and risk of traffic accident/impairment. From 
the relevant literature regarding central stimulant agents, several of their effects may not be compati-
ble with safe driving, and even low concentrations might lead to substantial reduction in driving ability. 
 
Benzoylecgonine was frequently detected in DUI cases. This cocaine metabolite is inactive, and was 
therefore not considered a candidate for legislative limits 
 
More details on the new Norwegian legal limits and impairment limits will be published (Vindenes et 
al., manuscript in accepted for publication in Forensic Science International.). 
 
Table 3: proposed limits for DUI in Norway. 
DRUGS Low limits (ng/mL in 
whole blood) 
Impairment limits com-
parable to 0.5 g/L BAC 
(ng/mL in whole blood) 
Impairment limits com-
parable to 1.2 g/L BAC 
(ng/mL in whole blood) 
Benzodiazepines and benzodiazepine-like 
Alprazolam 3 6 15 
Clonazepam 1.3 3 8 
Diazepam 57 143 342 
Fenazepam 1.8 5 10 
Flunitrazepam 1.6 3 8 
Nitrazepam 17 42 98 
Oxazepam 172 430 860 
Zolpidem 31 77 184 
Zopiclone 12 23 58 
Cannabis    
THC 1.3 3 9 
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DRUGS Low limits (ng/mL in 
whole blood) 
Impairment limits com-
parable to 0.5 g/L BAC 
(ng/mL in whole blood) 
Impairment limits com-
parable to 1.2 g/L BAC 
(ng/mL in whole blood) 
Central stimulants    
Amphetamine 41 * * 
Cocaine 24 * * 
MDMA 48 * * 
Methamphetamine 45 * * 
GHB    
GHB 10 300 30 900 123 600 
Hallucinogens    
Ketamine 55 137 329 
LSD 1 * * 
Opioids    
Buprenorphine 0.9 * * 
Methadone 25 * * 
Morphine 9 24 61 
 
*Limits have not been suggested because the correlation between drug concentration and risk of traf-
fic accidents/impairment is variable or insufficiently documented. For instance, marked impairment can 
be seen at low concentrations for substances like amphetamine and methamphetamine, in particular 
some time after substantial drug intake. 
 
5.1.2 The Netherlands 
 
Up to now in the Netherlands only legal limits for alcohol (novice drivers: 0.2 g/L, others: 0.5 g/L BAC) 
are determined. But as in Norway an expert group working on the definition of legal limits for particular 
drugs was implemented and is proposing new guidelines. It was decided to define limits only for single 
drug use, related to effects in new users and the time period between stop by the police and blood 
sampling should be limited. The cut-offs are understood as an impairment approach, as they are re-
lated to effects. In case these cut-off values are reached, no “additional” sign of impairment is re-
quired. 
 
For 10 substances cut-offs for blood and plasma have been defined by using different sources of in-
formation (e.g. published research results, (6, 7)), see Table 4. 
 
Table 4: Cut-offs in plasma and whole blood proposed by the Dutch working group. 
 
Drug Analyte that is measured Cut-off in 
plasma(ng/mL) 
Cut-off in 
blood(ng/mL) 
Amphetamine Amphetamine 50* 50* 
Methamphetamine Methamphetamine 50* 50* 
MDMA MDMA 50* 50* 
MDEA MDEA 50* 50* 
MDA MDA 50* 50* 
Cannabis THC 5 3 
Cocaine Cocaine 50 50 
Heroin Morphine 20 20 
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Morphine Morphine 20 20 
GHB, GBL, 1,4-butanediol GHB 10 mg/L 10 mg/L 
 
For defining the cut-offs of stimulants a pragmatic approach was chosen. As stimulant use is often 
combined with sleep deprivation, which causes driving impairment the cut-offs are fixed following the 
pharmacokinetic profile of regular stimulant use after a night of sleep loss. Because all stimulants are 
acting in the same way, and there are no prominent differences in their potency, the same cut-offs 
were chosen. In addition the setting of use plays an important role. The cut-off for THC was derived 
from publications as the comprehensive review of Grotenhermen (8).  
 
One criticism stated from some DRUID partners was that the long half-life of stimulants has to be con-
sidered thus it can be assumed that at these low cut-offs no impairment can be observed anymore. 
However, the rationale given in Norway and The Netherlands for the choice of the cut-offs addresses 
this criticism. The other point is that the main reason for driving impairment is the sleep deprivation 
and not the drug intake itself. But the question can be raised if this lack of sleep could be possible 
without the use of drugs. 
 
One should realize that despite the fact that these cut-offs have been determined based on the most 
recent literature data, they are still approximations, and a having a concentration of drug under the 
cut-off does not automatically mean that the drug cannot be the explanation for the impairment ob-
served in a subject. But this is also the case for alcohol, where some subjects can be impaired even 
when their blood alcohol concentration is lower than 0.5 g/L, which is the legal limit in most EU mem-
ber states. 
 
5.1.3 Denmark 
 
In Denmark all illegal and legal drugs with abuse potential (e.g. opioids) are forbidden in the traffic 
above a fixed concentration limit in whole blood. Legal drugs are excepted in case one has a prescrip-
tion and one is judged able to drive in a sure manner (investigated by a medical doctor).  
 
For therapeutic drugs, e.g. morphine, the limits were selected as the lower therapeutic limits taken 
from the literature (in practice serum concentrations; most drugs have about equal distributions in 
blood/serum), e.g. for morphine, e.g. 0.010 mg/kg. As sources, the compilation by Schulz & Schmoldt 
(9), and other sources in textbooks were used. Schulz & Schmoldt is a source that is fully referenced 
and so this source was used in most cases.  
 
Concerning illegal drugs with no therapeutic use, the lower limit for pharmacological effect was used if 
available, or a concentration level documented to correspond with intake of usual abuse doses (e.g. 
drugs as cathine or cathinone). For the most frequently abused drugs that have limits established in 
other countries, these limits were also taken into account, e.g. for THC, although it is known that the 
limit for actual proven disability to drive safely is a little higher than 0.001 mg/kg in case of THC. How-
ever, for THC one should also be aware of the fast elimination during the first few hours following drug 
use that often will give a low concentration at the time of sampling. Thus, given a concentration of 
0.001 mg/kg it is likely that a level associated with impaired driving was present in the preceding hours 
(there may be some special considerations in relation to chronic abuse). 
 
Metabolites (inactive) are not included because the Danish legislation is confined to active sub-
stances. This is a limitation for e.g. cocaine, where benzoylecgonine cannot be used. 
 
In the lab, 50% is added to the legal limits to take measurement uncertainty into account and deliver 
an answer: whether a drug is present or not present in relation to these limits.”(Prof. Kristian Linnet, 
Department of forensic medicine in Copenhagen, personal communication). 
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5.2 Comparison of the proposed cut-offs. The problem with stimulant 
drugs.  
 
 
Table 5 compares the proposed cut-offs equivalent to 0.5 g/L ethanol. One can observe quite a good 
agreement between the cut-offs proposed in the Netherlands and Norway, except for cocaine (double 
in the Netherlands compared to Norway) and GHB (3 times higher in Norway). In the document of 
Prof. Berghaus et al (D1.1.2b), the value for THC is lower than that obtained in Norway and The Neth-
erlands. This limit is a raw value derived from experimental studies with the corresponding impairment 
at 0.5 g/L ethanol. For the definition of a legal limit one has to add a measurement error and thus one 
reaches the same values as Norway and the Netherlands.  
Regarding the effect of stimulants it is written in D1.1.2b (10) that “at least with respect to driving-
related performance there seem to be no statistically significant impaired effects that exceed the 15% 
threshold” (limit equal to impairment seen with 0.3 g/L ethanol). They also state “Hence, concerning 
driver fitness as tested with “normal” doses (40 mg - 125 mg) in experimental studies, the risk potential 
of ecstasy comprised during the time of action primarily not the impairment of performance. 
 
Summary of DRUID findings regarding stimulant effects: 
• Experimental studies: MDMA (25, 50 and 100 mg) and dexamphetamine (10, 40 mg) did not 
impair performance in a standardized on-road test of driving performance (SDLP; a measure 
of lane-keeping performance). But the stimulating effects of MDMA and amphetamines are not 
sufficient to overcome or compensate driving impairments produced by concomitant alcohol 
use or sleep deprivation (D 1.2.1). A meta-analysis of experimental studies revealed that there 
are more findings of performance improvement than of performance impairment (D 1.1.2b) 
under influence of stimulating drugs. But consumers of stimulating drugs may not be aware of 
post acute fatigue and thus need to be educated about this effect and its possible implications 
on driving safety (D 1.2.1).  
• Stimulant use is often accompanied by sleep deprivation. Sleep deprivation itself causes the 
same degree of impairing effects as the influence of 0.8 g/L BAC (D 1.2.1). 
 
Epidemiological studies: 
• The odds ratios of responsibility for amphetamines, cocaine and opiates are not significantly 
different from 1, which indicates that the probability of being responsible for a fatal crash is not 
increased (D 2.3.2).  
• The odds ratios of the case control studies indicate a significantly increased accident risk with 
high concentrations of amphetamines. This result should be interpreted with care, because the 
numbers of cases and controls are low and by adding or subtracting one case the OR became 
not significant (D2.3.5). 
 
 
On the other hand non-experimental studies and case reports performed before DRUID revealed 
negative effects of amphetamines in terms of driving safety in the effective phase such as euphoria, 
agitation and confusion, increased risky behaviour, overestimation of one’s own possibilities, restricted 
critical thinking and inner restlessness. Furthermore, the effects after an acute intoxication with am-
phetamines are frequently characterised by sleepiness and exhaustion, which are, of course, of spe-
cial relevance for traffic safety. These circumstances seemed to comprise at least a certain risk for a 
safe participation in motor traffic. But on the one hand there was no information about the frequency of 
such effects and on the other hand one has to ask why these deficits did not lead to severe impair-
ment in performance tested in experimental studies. 
 
It seemed that the experimental research as done currently is at the frontier of its possibilities in this 
situation. May be it would be of interest to compare in an experimental approach the point of time and 
the concentration of amphetamine in blood when the increased performance not further overlaps the 
increased risky behaviour or the overestimation of one’s own capacity (quote from Deliverable 1.1.2b). 
In the Norwegian evaluation, a similar conclusion (since the available literature regarding the central 
stimulants did not provide evidence for dose-response effects, limits for graded sanctions were not 
suggested) was made. 
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Table 5: Comparison of the proposed cut-offs in whole blood in Norway (impairment limit corresponding to 0.5 g/L 
ethanol) and the Netherlands and Denmark with the cut-offs suggested by Prof. Berghaus for some selected 
drugs. All concentrations are given in ng/mL (or μg/L). 
 Norway The Netherlands Denmark Berghaus (10) 
DRUID D1.1.2b 
Amphetamine 41* 50 20 NR 
Methamphetamine 45* 50 20 NR 
MDMA 48* 50 20 NR 
THC 3 3 1 2** 
Cocaine 24* 50 20 NR 
Morphine 24 20 10  
* Limits are equivalent to 0.2 g/L ethanol. Limits equivalent to 0.5 g/L ethanol have not been sug-
gested because the correlation between drug concentration and risk of traffic accidents/impairment is 
variable. 
** Mentioned as 3.8 ng/mL in serum after smoking, 3.7 ng/mL in serum after oral consumption 
NR: not reached: no studies showed that impairment was an effect of acute amphetamine or cocaine 
use. See text for more details. 
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6 Relationship between blood concentration and effect 
 
Many lay people suppose that there is a good relationship between drug concentrations in blood and 
the effect (Figure 3). However this is rarely the case. It is more or less the case for alcohol, but even 
there, there are some differences. Figure 4 shows that in a very old publication, the maximum intoxica-
tion score for alcohol comes earlier than the peak concentration and that the intoxication decreases 
more rapidly than the blood alcohol concentration. This is also illustrated in the concentration-effect 
relation shown in Figure 5. 
 
 
Figure 3: Ideal concentration-effect curve. 
In principle, the effect should be related to the concentration in the brain or at the site where the drug 
exerts its effects.  
 
Figure 4: Comparison of the blood alcohol concentration and the symptoms of intoxication. (11) 
The effect of a drug, e.g. the ‘high’ experienced when using a drug, is more related to the rate of in-
crease in the concentrations than to the absolute concentration itself. The abuse liability of a drug is 
enhanced by rapidity of onset because effects that occur soon after administration are more likely to 
initiate the chain of events that leads to loss of control over drug-taking. The pharmacokinetic vari-
ables influence the time it takes a drug to reach critical receptor sites in the brain. The history of co-
caine use illustrates the changes in abuse liability of the same compound, depending on the form and 
the route of administration. When coca leaves are chewed, cocaine is absorbed slowly through the 
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buccal mucosa. This method produces low cocaine blood levels and correspondingly low levels in the 
brain. The mild stimulant effects produced by the chewing of coca leaves have a gradual onset, and 
this practice has produced few, if any, behaviour problems despite use over thousands of years by 
natives of the Andes mountains. Beginning in the late 19th century, scientists isolated cocaine hydro-
chloride from coca leaves and refined the technology for extraction of pure cocaine. Cocaine could be 
taken in higher doses by oral ingestion (gastro-intestinal absorption) or by absorption through the na-
sal mucosa, producing higher cocaine levels in the blood and a more rapid onset of stimulation. Sub-
sequently, it was found that a solution of cocaine hydrochloride could be administered intravenously, 
giving a more rapid onset of stimulatory effects. Each newly available cocaine preparation that pro-
vided greater speed of onset and an increment in blood level was paralleled by a greater likelihood of 
addiction. In the 1980s, the availability of cocaine to the American public was increased further with 
the invention of crack cocaine. Crack, sold illegally and at a low price ($1-3 per dose), is alkaloidal 
cocaine (free base), which can be readily vaporised by heating. Simply inhaling the vapours produces 
blood levels comparable to those resulting from intravenous cocaine owing to the large surface area 
for absorption into the pulmonary circulation following inhalation. The cocaine-containing blood then 
enters the left side of the heart and reaches the cerebral circulation without dilution by the systemic 
circulation. Thus, inhalation of crack cocaine is much more addictive than chewing, drinking, or sniffing 
cocaine. Inhalation, with rapid attainment of effective drug levels in the brain, also is the preferred 
route for users of nicotine and cannabis. (12) 
 
 
Figure 5: Concentration-effect relationship for alcohol. Immediately after intake, the effect increases more rapidly 
than the blood concentration, while the reverse is true later on (t4 - t6). 
For some drugs like cannabis, the effects come later than the peak blood concentration, a phenome-
non that is called hysteresis (Figure 6). From this figure, it appears clearly that one cannot expect a 
good relationship between the concentration of the drug in the blood and the effect. A low concentra-
tion in the blood can correspond to a severe effect or to a relatively minor effect. This being said, the 
phase corresponding to t1 to t3 in the figure is very short, corresponding to the actual smoking of the 
joint. The period of most relevance for driving is t4 to t6, which shows that the effect continues for a 
long time even if the concentration decreases, hence the placing of the lower effect limit at the de-
scending part of the curve.  
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Figure 6: Example of a hysteresis curve for cannabis, where after intake (t1 to t3) the blood concentration in-
creases more rapidly than the effects. Later on, (t3 - t4) the concentration is stable but the effect increases. The 
concentration at time t1 and t6 corresponds to low effects (t1) or maximal effects (t6). This illustrates the problem 
of setting a cut-off: for a similar affect (blue dashed line), the concentration corresponding to the effect could be 
low or high. As t1 – t3 is a short period corresponding to smoking, the lower effect cut-off should be placed at the 
left-most crossing point of the red curve and the dashed blue line (red circle). 
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7 Which scientific data can be used for the establishment of “lower effect 
limits” and “risk thresholds”? 
 
7.1 Which scientific data can be used for the estimation of substance 
related accident risk? 
 
Setting a concentration threshold for a psychoactive substance in traffic means to presume that a 
driver exceeding this limit is likely to be unfit to drive and may be prosecuted without further evidence. 
With respect to this consequence, it becomes immediately evident that on the one hand the decision 
for a concentration limit must be based on empirical results about the impairing potential but on the 
other hand cannot be restricted to those empirical results alone. Especially in case of psychoactive 
substances, the behavioural variance between persons is extremely high. Therefore, the relation be-
tween substance concentration and behavioural impairment (consequently driving fitness) will only be 
a probabilistic one. The higher a concentration limit is, the more likely impairment can be assumed for 
all drivers. As a consequence, the result of empirical studies – either epidemiological or experimental 
ones – is only one part of the discussion about reasonable concentration limits, albeit an important 
one.  
 
To justify a limit, other questions must be answered like: How precise can concentrations be meas-
ured? How large is the deterrence effect of per se limits? Is the accepted risk for therapeutic drug-
induced impairment the same as for recreational drugs? Therefore, the following compilation and dis-
cussion of empirical results about substance-induced impairment will only yield a framework for the 
much broader discussion about setting concentration limits. 
 
7.2 Discussing pros and cons of different types of studies 
 
7.2.1 Epidemiological studies  
 
The most relevant information, besides political or ethical considerations, in order to determine thresh-
olds is the information about the accident risk in traffic dependent on different concentrations of single 
substances. Direct information about the accident risk in traffic can only be gained by conducting epi-
demiological studies. Representative studies on prevalence in accident-free and accident populations 
are difficult and expensive. Especially for substances with a low exposure rate in the population, a 
huge sample ought to be examined in order to get reliable estimations. Thus, for most of the sub-
stances, either legal or illegal, the data necessary for calculating risk indices are missing or incom-
plete, which leads to substantial problems for the estimation of traffic risks. Therefore experimental 
data should fill the knowledge gaps.  
 
It is important to know the limitations of the single epidemiological study type in order to be able to 
weigh the results regarding their validity. Relative merits of experimental and epidemiological ap-
proaches are already described in literature (13, 14), thus in the following some remarks will be made. 
 
Case control-studies are conducted mostly in the form of roadside prevalence data compared with 
accident data derived from hospital cases. Here it is important that the substance concentrations in the 
same body fluids are measured. There are very few data on the relationship between the presence 
and concentration of drugs and alcohol and the severity of the accident. Smink et al. (15, 16) found 
that there is no clear association between use of psychoactive substances and the severity of crash-
related injury. Also all toxicological limitations have to be taken into account when interpreting the risk 
estimations of an epidemiological study e.g. how much time after the accident or even death was the 
sample drawn? 
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By comparison of odds ratios from these case control studies with those of responsibility studies one 
has to suggest if the risk estimation of the same substance concentration will lead in both study types 
to the same odds ratio or if methodological differences may influence the OR. To get at least a feeling 
of comparability and integrability of study results resulting from different methodologies, a reference 
curve is helpful. For instance alcohol data delivered with these different study methodologies could be 
used as the gold standard (this will be the case in DRUID D1.3.1). 
 
In cases where low prevalence epidemiological data do not allow risk calculation (odds ratios) of dif-
ferent concentration ranges from single psychoactive substances the results of experimental studies 
should be taken into account. 
 
7.2.2 Experimental studies 
 
Experimental studies allow substance concentration dependent investigations on driving behaviour. 
One of the most criticisms is that it seems doubtful to draw conclusion on driving impairment from 
some driving parameters as for instance the SDLP (standard deviation of lateral position). Reference 
values from alcohol data may help to interpret the drug effects on driving parameters, but one has to 
keep in mind that alcohol and drugs do not act in the same way especially if drugs belong to the group 
of stimulants. In several experimental studies stimulants do not show impairing effects that are related 
with save driving behaviour, but can we follow only on basis on these studies that under stimulant 
influence driving is safe? One limitation in experiments is that very low doses are used for ethical rea-
sons and only higher drug concentrations will deliver impairing effects.  
 
Concerning the effects of stimulants the DRUID expert group agreed on: 
 
“Post acute effects”, that means impairing effects not caused by the drug action but caused after the 
drug action by the symptoms of “hang over” will be excluded for the determination of cut-offs.  
 
This is similar with the procedure of determining the alcohol limit. If impairment would be measured 
the next morning after a lot of alcohol consumption, impaired performance could be detected below a 
BAC of 0.5 g/L. For alcohol we only sanction its presence in blood or breath. This could be the same 
for all illegal drugs, despite the fact that many substances afterwards cause deterioration as well (post-
acute phase). 
 
Concerning experimental data on medicinal drug effects one has to see that medicinal drugs have 
mainly been tested in drug naive, healthy volunteers, whereas studies investigating the effect of illegal 
drugs are conducted with occasional drug users.  
 
The DRUID expert group decided that for illegal drugs as well as for illegal medicine use all studies 
investigating the effect of chronic consumption should be neglected. Cut offs should be defined for 
occasional users not for regular ones as they develop habituation on substance levels which are too 
high for their appliance on occasional users. 
Regarding the application of legal regulations one has to differentiate the prescribed and intended 
intake of medicines from illegal or not intended use of medicines. 
 
7.2.3 Pharmacokinetic data (e.g. detection time)  
 
In case not enough scientific studies – whether epidemiological nor experimental - are available, 
pharmacokinetic data could support the determination of cut-offs. For defining the pharmacokinetic 
profile of medicines one should take the usual prescribed dose and for defining the profile for illegal 
drugs one should figure out the usual consumption amount of occasional drug users. The cut-off could 
then be set at a certain time after use, e.g. the duration of the effects or pragmatically, four times the 
half-life of the substance. This approach was chosen by the countries described in 5.1. Denmark, 
Norway and the Netherlands defined stimulant/cocaine cut offs on the basis of pharmacokinetic data 
applying different methodological ideas (see 5.2). Whereas the cut-offs for Norway and the Nether-
lands are quite similar, for cocaine the pharmacokinetic approach from Denmark leads to different 
values. Pharmacokinetic profiles for stimulants are analysed and calculated in D 1.1.2b (10). 
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8 Establishing a list of criteria for defining cut-offs 
 
Which criteria should be used for the determination of cut-offs in general? 
 
Experimental and epidemiological results should be interpreted together for the determination of cut-
offs. 
 
Recommendations have to be developed concerning substances if the criteria list is not applicable. 
For instance, pharmacokinetic data may be used when there are not enough scientific results.  
 
8.1 Selection of the psychoactive substances for which cut-offs should 
be determined 
 
8.1.1 Determination of substances, prevalence based 
 
It seems logical to limit the list of drugs for which per se limits are given. In many countries, the list is 
very limited, and contains less than 10 analytes. In Victoria in Australia, the list is limited to 3 sub-
stances: THC, methamphetamine and MDMA. 
 
For the selection of analytes, the prevalence in roadside surveys or in injured or killed drivers is a 
good starting point. The results in the epidemiological studies in DRUID have shown that the preva-
lence can vary markedly among different countries. 
 
Most countries have started with only illicit drugs, because these have no medical use, and it is less 
controversial to include them. 
 
It is not a problem to limit the list to a few substances, if the per se law is combined with an impairment 
law, where all other impairing substances are covered. In this scenario, a quick and easy to enforce 
procedure exists for the most common drugs, and a more elaborate procedure exists for the less fre-
quent cases, including medicinal drugs, combination of drugs, withdrawal, etc. We don’t think it is real-
istic to develop cut-offs for all the existing medicinal and recreational drugs. Moreover for new drugs, it 
might take some time before the different cut-offs have been established. 
 
8.1.2 Should metabolites be included? 
 
In most cases, per se legislation will be limited to the parent drugs and/or active metabolites. Even if 
the name of ‘per se’ or ‘zero-tolerance’ legislation doesn’t imply it, legislators and experts who deter-
mine the cut-offs have set them so that the presence of a drug above the cut-off concentration gener-
ally means that the person will be impaired. However, in some cases, it is necessary to include me-
tabolites, e.g. when the parent drug is unstable and is metabolised very rapidly, e.g. heroin has a half-
life of 3 – 6 minutes and its active metabolite 6-acetylmorphine also has a short half-life and is unsta-
ble in blood. In that case, morphine is used, but it is also active. 
 
Cocaine is very unstable in blood that is not preserved with fluoride, so in these cases the inactive 
metabolite benzoylecgonine is monitored. 
As cocaine is very unstable in blood it should be preserved by using sampling tubes with added fluo-
ride. If a country decides to include inactive metabolites as benzoylecgonine the cut-off should be so 
high that cocaine consumption long time ago (e.g. 12 hours as time for post acute effects) can be ex-
cluded. 
 
Some nitrobenzodiazepines like clonazepam, flunitrazepam and nitrazepam are very unstable in blood 
(17, 18), and their 7-aminometabolites should be measured.  
 
The inclusion or not of metabolites will depend on the choice of matrix, storage conditions and pre-
servatives added in the sampling tubes. 
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It might also be useful to detect metabolites, not because they are included in the per se legislation, 
but because they increase the level of certainty of the toxicological determination (3). 
 
8.1.3 How to deal with combined consumption? 
 
Much research, including that in DRUID, has shown that the combination of alcohol and drugs, or the 
combination of more than one drug, increases the accident-risk exponentially.. If one applies the cut-
offs defined for single use for combined use as well one would accept an increased accident risk. 
 
One could argue that in case more than one drug (including alcohol) is present, the cut-offs don’t 
count, and if the drugs are present above the lower limit of quantitation, the subject can be prose-
cuted. This has been recommended in WP 6 (19). 
 
8.1.4 How to deal with the interval between the accident and the blood sampling? 
 
In many cases, the delay between the police stop or the accident and the sampling of blood is one 
hour or more. In the DRUID hospital study, the median time between the accident and sampling was 
1.17 hours. But some drugs, like THC, have a very short half-life, particularly in the first hours after 
smoking. For THC, the half-life of the distribution phase is 1.4h ± 0.1 h (20). If the concentration at the 
time of the accident was 3.0 ng/mL whole blood, 1.5 hours later it will only be 1.43 ng/mL.  
 
For ethanol, back-calculation is used in many countries, but for drugs, because of the variable phar-
macokinetics, back-calculation is very rare. 
 
In order to deal with this, several approaches are possible: one could set the limit lower in order to 
compensate for the delay between the accident or the police stop and the sampling, or one could al-
low for back calculation, but this should be standardised among all experts in one jurisdiction. Many 
toxicologists are reluctant to use back-calculation, considering the many assumptions that have to be 
made. 
 
8.1.5 How to deal with legal prescribed medicine use? 
 
For this topic a DRUID expert group conducted a workshop with the following results. 
 
A properly prescribed medicine includes right information of the patient by the practitioner. Patients in 
long-term treatment with psychoactive medicines should not be stigmatised by the need to carry a 
special “medication passport”. Other than with drug users, the responsibility and compliance of pa-
tients under long-term treatment usually is high. 
 
It is not reasonable to define cut-off values for patients in long-term treatment. Even high doses may 
lead to fewer effects. The correlation between dosage and impairment is only intra-individual. There is 
no clear inter-individual correlation. Dosage effects were only investigated and observed with single 
users or new users. Hence, an impairment check is an objective way to judge recreational use. 
Alcohol increases impairment and interacts with many medicines in an unfavourable way. Hence, a 
separation of drinking, medicine consumption and driving is necessary and the respective information 
should be part of the physician’s consultation. 
 
8.1.6 How to deal with tolerance? 
As is the case for alcohol, there are no special cut-offs that take tolerance into account for the cut-off 
calculation.  Cut offs will be defined primarily for occasional (regular) drug users. 
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9 Requirements for analytical methods 
9.1 Analytical methods used in DRUID 
 
Within the epidemiological studies, 13 countries collected whole blood, oral fluid, dried blood spots, 
plasma or urine from injured drivers in hospital studies and/or from the general driving population dur-
ing roadside surveys. When the project started, the level of laboratory instrumentation, methodology 
and expertise varied remarkably between countries. Standardisation, development of laboratory proc-
esses, training of staff members and problem solving by study visits to partner laboratories were 
needed. Requirements were set at the very beginning of the project for ensuring the reliability of the 
analytical methods used in different laboratories.  
 
Standardisation of data collection and toxicological analysis was very important to allow correct com-
bination of study results. Therefore, several aspects of the toxicological analyses of the oral fluid and 
whole blood samples like collection and transportation guidelines, target analytes, analytical cut-offs 
and analytical methods, had to be standardised. This was done in combination with joint epidemiologi-
cal guidelines for the study protocols (21). Since other matrices such as dried blood spots and urine 
were only collected in small numbers (and were not used for the epidemiological analysis), no specific 
guidelines have been developed for these matrices (22). 
 
Twenty-three psychoactive substances were analysed by LC–MS/MS or GC–MS in SIM-mode by all 
laboratories using the same analytical cut-offs. All laboratories participated in external quality assess-
ment programs (proficiency testing) to further improve comparability of results. The standardisation, 
requirements and training produced very good results that could be shown by the inter-laboratory pro-
ficiency testing results.  
 
The specimens in the epidemiological studies were blood, oral fluid and urine; in the experimental 
studies serum and plasma. Whole blood was used in the epidemiological studies because legislation 
in most countries was based on whole blood and transportation was easier since haemolysis was not 
a concern. Correct collection of plasma was difficult in epidemiological studies because transportation 
conditions and fluoride preservatives (necessary to prevent cocaine degradation) could cause hae-
molysis, which makes centrifugation and separation of plasma necessary at the site of collection. 
Given the facts that sample clean-up of plasma is easier and that collection and transportation of 
samples is easier to control in experimental studies, plasma is widely used in experimental studies. 
For practical reasons, most countries collected oral fluid in the epidemiological roadside survey and 
whole blood in the hospital study. 
 
Literature on the correlation of the analyte concentrations in different body fluids is limited and indi-
cates only a weak or absent correlation between blood and oral fluid concentrations since the ratios 
between these body fluids show inter individual variation, but can also be time-and dose dependent as 
well as dependent on collection method of OF (20, 23-26). Literature on pharmacokinetics on the other 
hand is based only on plasma concentrations. 
 
The main problem for comparison of results was therefore the combination of results obtained from 
the analysis of different body fluids. This problem was investigated in DRUID by collection and analy-
sis of different sample types collected from the same study persons. The findings from DRUID were 
used to partially solve these problems. 
 
9.1.1 Consensus on the substrate 
 
Target analytes were selected based on suspected impairing effects and prevalence of the sub-
stances. They were active drugs or their active metabolites except benzoylecgonine, the metabolite of 
cocaine, because of the stability problem of cocaine.  
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Project partners had been asked to give their opinion on the relevance of a preselection of analytes. 
This assessment by the individual partners was both based on (suspected) impairing effects and pre-
valence in the respective countries. Twenty-three drugs were chosen by at least 9 countries and were 
included in the ‘core list’ for which analysis was mandatory in all the 13 countries. 
 
This core list includes ethanol, illicit drugs and their metabolites (amphetamine, MDMA, MDA, MDEA, 
methamphetamine, cocaine, benzoylecgonine, THC, THC-COOH, 6-acetylmorphine), hypnotics and 
sedatives (zolpidem, zopiclone, flunitrazepam), anxiolytics (diazepam, alprazolam, nordiazepam, oxa-
zepam, lorazepam), opiates and opiates and medication for substitution treatment (morphine, codeine, 
methadone), and an antiepileptic agent (clonazepam) (Table 6). 
 
Table 6: Core list of target substances and the cut-off values in whole blood and oral fluid. 
Core Substance Whole blood analytical cut-off (ng/mL) Saliva analytical cut-off (ng/mL) 
Ethanol 0.1 g/L 0.1 g/L 
6-acetylmorphine 10 5 
Alprazolam 10 1 
Amphetamine 20 25 
Benzoylecgonine 50 10 
Clonazepam 10 1 
Cocaine 10 10 
Codeine 10 20 
Diazepam 20 5 
Flunitrazepam 2 1 
Lorazepam 10 1 
MDA 20 25 
MDEA 20 25 
MDMA 20 25 
Methadone 10 20 
Methamphetamine 20 25 
Morphine 10 20 
Nordiazepam 20 1 
Oxazepam 50 5 
THC 1 1 
THCCOOH 5 NR 
Zolpidem 20 10 
Zopiclone 10 10 
 
In order to include more classes of medicinal drugs, all countries were asked to individually add at 
least three more analytes. As a result, in total 28 additional drugs were included as ‘national drugs’ 
(Table 7). The extra substances belong to the drug groups that were already present in the core list, 
but also include antihistamines, antidepressants (both SSRI’s, non-selective monoamine reuptake 
inhibitors and other antidepressants) and antipsychotics: 7-aminoclonazepam (metabolite of clonaze-
pam, 12 countries), 7-amino-flunitrazepam (metabolite of flunitrazepam, 11 countries), tramadol (8 
countries), amitriptyline and nitrazepam (6 countries), buprenorphine (5 countries), bromazepam (4 
countries), diphenhydramine and midazolam (3 countries), 11-OH-THC, carisoprodol, (es)citalopram, 
meprobamate, mirtazapine, temazepam, trazodone (2 countries), carbamazepine, chlordiazepoxide, 
ecgonine methyl ester (metabolite or break-down product of cocaine), fluoxetine, haloperidol, imipra-
mine, ketamine, melperone, olanzapine, phenazepam, venlafaxine and zaleplon (1 country).  
 
Table 7: The list of additional substances measured in some countries. 
Substance Whole blood analytical cut-off 
(ng/mL) 
Saliva analytical cut-off 
(ng/mL) 
11-OH THC 1 NA 
7-Aminoclonazepam 10 1 
7-Aminoflunitrazepam 2 1 
7-aminonitrazepam 10 1 
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Substance Whole blood analytical cut-off 
(ng/mL) 
Saliva analytical cut-off 
(ng/mL) 
Acetamidoclonazepam 1 1 
Acetamidonitrazepam 1 1 
Amitriptyline 10 10 
Bromazepam 20 5 
Brotizolam 1 1 
Buprenorphine 1 1 
Carbamazepine NA 10 
Carisoprodol 500 50 
Chlordiazepoxide 20 10 
Citalopram 5 5 
Clobazam 5 5 
Demoxepam 10 10 
Desalkylflurazepam 2 2 
Desmethylchloordiazepoxide 8 8 
Desmethylclobazam 5 5 
Desmethylflunitrazepam 1 1 
Diphenhydramine NA 10 
Fluoxetine 10 5 
Flurazepam 2 1 
Imipramine NA 10 
Ketamine 20 20 
Levomepromazine NA 10 
Lormetazepam 1 1 
Meprobamate 2000 1200 
Methylecgonine 5 5 
Midazolam 10 2 
Mirtazapine 5 5 
Nitrazepam 1 2 
OH-alprazolam 1 1 
OH-ethylflurazepam 2 2 
OH-midazolam 1 1 
OH-triazolam 1 1 
Temazepam 20 10 
Tramadol 50 50 
Trazodone 10 5 
Triazolam 1 1 
 
9.1.2 Standardisation of collection and methods 
 
Collection and transportation conditions were selected so that they should ideally ensure stability of all 
compounds in the different sample types. Literature on this issue is limited for most analytes. It was 
however clear that within the ‘core list’, cocaine is the most unstable compound during transportation. 
Since cocaine degradation in whole blood is 22.9% per day at 20 °C and only 4.5% per day at 4 °C, it 
was critical that samples were transported at 2–8 °C (27). Transportation was not allowed to last more 
than 48 h. After transportation, samples had to be stored at −20 °C prior to analysis. Whole blood (5–
10 mL) was collected using glass Vacutainer-type tubes containing sodium fluoride and potassium 
oxalate. 
 
The type of device used for oral fluid collection was critical since this strongly influences the concen-
trations present (28). The device had to allow fast and easy collection, ensure good stability and re-
covery of illicit and medicinal drugs and provide enough samples for toxicological analysis. Ten devic-
es were compared on these criteria. Finally, the StatsureTM saliva sampler (Statsure Diagnostics Sys-
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tems, Framingham, MA, USA) was chosen. All tested substances had a recovery >80% and good 
results for stability over 28 days (29). 
 
9.1.3 Analytical methods 
 
Since only a small volume of sample was available, all laboratories had to develop methods for simul-
taneous detection of the target analytes. All laboratories agreed to use either LC–MS/MS or GC–MS in 
SIM-mode. The choice of technique for the determination of ethanol was open, quantitative breathana-
lyser results were accepted for use as well. Several analytical methods used for the analysis have 
been published or presented at international meetings (30-36). 
 
9.1.4 Quality assurance 
 
The laboratories implemented planned and systematic activities within their quality system, to provide 
adequate confidence that the results fulfilled the requirements for quality set in DRUID. The laborato-
ries improved their quality control, the overall system of laboratory procedures and processes that 
controlled the quality of the laboratory’s analytical results. Methods used in DRUID had to be devel-
oped, evaluated and tested to ensure that they produce valid results at the agreed levels. The me-
thods had to be validated in order to confirm that the requirements in DRUID are fulfilled. Performance 
characteristics of the analytical methods were evaluated, including e.g. the ability to get the true re-
sults (accuracy /bias), linearity, limit of detection (LOD), lower limit of quantitation (LLOQ), recovery, 
precision/ repeatability, reproducibility, ruggedness, specificity (selectivity), matrix effect and uncertain-
ty of measurement (4).  
 
The analytical cut-off concentrations (or thresholds) were decided in DRUID and all the laboratories 
had to have methods sensitive enough to reach the set cut-offs. A cut-off is the agreed concentration 
of a drug in a specimen that is used to determine whether the specimen is considered positive or neg-
ative. The cut-off had to be higher than the limit of detection. (4).  
 
The ability to quantify was evaluated by LOQ. The limits of quantitation should not have been higher 
than the established cut-off values in DRUID.  
 
Analytical cut-offs were established for the core list based on those used in ROSITA-2 (37), SAMHSA 
cut-off values (38) for oral fluid and recommendations from an expert meeting in Talloires (39) (Table 
6). Because of practical and legal considerations, different sample types were used: whole blood, se-
rum/plasma and oral fluid and cut-offs were determined for oral fluid, serum/plasma and blood.   
 
9.1.5 Proficiency testing 
 
Proficiency testing schemes were used to monitor and compare the participating laboratories’ perfor-
mance against that of other partners’ laboratories in producing equivalent data. Even with the tight 
standardisation efforts, differences between laboratories may still occur. These were detected by pro-
ficiency testing (PT) for both oral fluid and whole blood, which were organised twice per year. In recent 
years several PT programs for drugs of abuse in oral fluid have started (40-42). For DRUID, a new 
program was specifically designed and organised by RTI International (Research Triangle Park, NC, 
USA): five samples of 1.5 mL of synthetic oral fluid (spiked with the ‘core list’ analytes) were distri-
buted to all DRUID laboratories every 6 months. Arvecon GmbH (Walldorf, Germany) organised a 
specific whole blood PT scheme. When problems in proficiency testing were detected, corrective ac-
tions were made and the proficiency testing results improved. The sample analysis started only after 
the proficiency testing results showed that the substances were detected and quantitated correctly. All 
measures were taken to reduce error probability. Some proficiency testing results are presented in 
Figure 8. The results of the oral fluid proficiency testing have been published (43).  
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Figure 7: Results of the proficiency testing in blood, 1st round of 2010 
 
 
 
Figure 8: Oral fluid PT: number of samples spiked with target analytes, concentration ranges and 
DRUID cut-offs. Sensitivity and specificity, minimum, maximum and average coefficients of variation 
(43). 
 
 
 
9.2 Measurement uncertainty 
 
Every measurement is subject to some uncertainty. Measurement uncertainties can come from the 
measuring instrument, from the item being measured, from the environment, from the operator, and 
from other sources. Such uncertainties can be estimated using statistical analysis of a set of mea-
surements, and using other kinds of information about the measurement process. There are estab-
lished rules for how to calculate an overall estimate of uncertainty from these individual pieces of in-
formation. The use of good practice – such as traceable calibration, careful calculation, good record 
keeping, and checking – can reduce measurement uncertainties (44). 
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The definition of the term uncertainty (of measurement) is: “A parameter associated with the result of a 
measurement, that characterises the dispersion of the values that could reasonably be attributed to 
the measurand” (45).  
 
There are different types of precision. The precision is a measure for the size of random errors. It 
measures the dispersion around the mean result and, therefore, it requires the calculation of the stan-
dard deviation of the measurement results. Precision can be determined at several levels. Repeatabil-
ity is measured under repeatability conditions, meaning that the operator, the instrument and the la-
boratory are the same, and the time interval is kept short. These are the most favourable conditions 
possible and they yield the best precision, (i.e., the smallest standard deviation). 
 
Reproducibility is defined as measured under "conditions where test results are obtained with the 
same method on identical test material in different laboratories with different operators using different 
equipment." It takes into account many more sources of variation than the repeatability does. These 
are the worst precision conditions that can occur when studying the precision of a method. It can be 
determined only with inter-laboratory method performance studies, colloquially known as collaborative 
trials. (46) 
 
Intermediate situations occur and give rise to an intermediate precision. They take into account 
more within-laboratory variations than when the precision is measured under repeatability conditions, 
such as the additional variation due to the measurements being performed over a longer period of 
time. The intermediate precision can then be seen as a measure of long-term precision in a given 
laboratory. 
 
A fourth somewhat different level is the determination of robustness (sometimes also called rugged-
ness). It measures to what extent a procedure is affected by small, deliberate variations introduced in 
the procedure. If one or more of these variations are found to be responsible for a significant differ-
ence in the results, the procedure must be adapted and more strictly controlled. If not, the method is 
considered robust, but the variations still lead to less precise measurements and robustness can 
therefore be seen as a measure of the intermediate precision or the reproducibility that might be ex-
pected. 
 
ISO uses the symbol r for repeatability and R for reproducibility. Repeatability and reproducibility are 
measured as the repeatability standard deviation, sr, and the reproducibility standard deviation, sR. 
For the intermediate precision ISO proposes the symbol I( ) with additional symbols inside the paren-
theses referring to the intermediate precision conditions. In this way s(TO)
 
, for example, means that the 
intermediate precision includes variability due to the time elapsed between measurements as well as 
due to the operator. 
The Horwitz curve gives an indication of the precision to be expected of a newly developed method as 
a function of the concentration of the analyte. It is named after W. Horwitz, a respected statistician, 
now retired from the Food and Drug Administration (FDA). Horwitz et al. initially examined results of a 
few thousand interlaboratory collaborative studies on various commodities ranging in concentration 
from a few percent (salt in foods) to the ppb (ng/g) level (aflatoxin M1 in foods) but also including stu-
dies on, for example, drug formulations, antibiotics in feeds and pesticide residues. They concluded 
that the predicted RSDR
 
 (%) as a function of concentration is approximated by the following relation-
ship: 
 
where C is the concentration expressed as a dimensionless fraction (for example for a concentration 
of 1μg/g, C = 10–6 g/g). In this context the predicted RSDR% is sometimes also written as σH, where 
the H stands for Horwitz. Equation 1 still holds for the 10000 interlaboratory studies that have been 
evaluated up to now. It states that σH
Table 8 some σ
 approximately doubles for every 100-fold decrease in concentra-
tion, starting at 2% for C = 1. The graphical representation of Equation 1 is referred to as the Horwitz 
curve and is shown in Figure 9. In  
H 
 
are calculated for some DRUID cut-offs for some analytes. 
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Figure 9: Relative reproducibility standard deviation RSDR
 
 as a function of concentration (46). 
Table 8: Predicted relative reproducibility standard deviation for some DRUID analytes (in%) at the cut-off, calcu-
lated with the Horwitz equation. 
Analyte DRUID cut-off σ
Ethanol 
H 
0.1 g/L 8% 
THC 1 ng/mL 45% 
Morphine  10 ng/mL 32% 
Oxazepam 50 ng/mL 25% 
THCCOOH 5 ng/mL 35% 
 
One of the more remarkable aspects of the Horwitz curve is its generality. It probably appears strange 
to the analyst that the reproducibility and the repeatability do not depend on the analytical method 
used. One of the reasons is that the method being investigated is studied intensively before an interla-
boratory study is undertaken, so that as many sources of variation as possible are kept under control 
by including the necessary specifications in the procedure to be followed. Thus, methods difficult to 
control or operating too close to detection limits, etc, will be not be subjected to interlaboratory studies. 
 
Another interesting result of the Horwitz study is that the corresponding repeatability measure (RSDr) 
is generally one-half to two-thirds of the reproducibility measure RSDR
 
. These repeatability figures are 
based on the repeatability of the laboratories participating in the interlaboratory studies that formed the 
basis of Horwitz's study. They are determined under the strict rules of ISO or the AOAC/IUPAC proto-
cols for such studies. Repeatabilities determined by individual laboratories outside such studies often 
tend to underestimate the variation and therefore yield too optimistic results. 
Uncertainty and the Horwitz Curve. 
 
The idea is to create an interval around the analytical result such that there is a 95% certainty that the 
true value is encompassed in it. This interval, known as the expanded uncertainty, is obtained as re-
sult ± 2sR. The value of σH derived from the Horwitz curve can be used as a best guess when sR is 
not known (yet). When a given maximum level of uncertainty is required for some application, for 
which the analytical method still has to be developed, the analyst can use σH to evaluate the probabili-
ty that the method will prove fit for its purpose. 
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Based on this information, the measurement uncertainty is approximately 30%-45% in the μg/L range. 
The measurement uncertainty that is used in Switzerland is 30%. In Denmark a measurement uncer-
tainty of 50% is used before a positive result is reported.  
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Part 2: Analytical findings in DRUID 
 
10 Toxicological and analytical findings in DRUID 
 
10.1 Determining the oral fluid to whole blood ratios for the DRUID core 
substances 
 
10.1.1 Introduction 
 
In the epidemiological studies of the DRUID project (WP2) both oral fluid (OF) and whole blood sam-
ples have been collected due to practical and legal considerations. Blood and urine are the tradition-
ally used sample matrices in drug testing, but recently the use of OF has increased due to its simple 
and noninvasive collection. Blood is used especially in driving under the influence (DUI) cases when 
proof of very recent drug use or possible impairment is needed. Detection times of drugs in OF better 
reflect the ones in blood than urine (47), which is mainly used to detect previously occurred or chronic 
drug use. In order to compare results from two different sample matrices the relationship of the drug 
concentrations between the two has to be determined (22). There have been studies on the subject 
where the connection between the concentrations has usually been determined by calculating the OF 
to whole blood (OF/B) or OF to plasma (OF/P) ratios for different drugs, but the results between the 
studies seem to differ quite a lot, and even within a single study the variation in the results can be 
more than 100% RSD (48). The concentration of drugs in OF depends on several variables, including 
the drug’s pKa, lipid solubility, molecular weight and plasma-protein-binding, and also on the dose and 
time of drug intake. Compared to blood, there is a delay for some drugs to be detectable in OF.  In 
addition, different sample collection methods may result in different concentrations, and also the inter-
individual differences in OF pH and salivary flow can affect the OF drug concentrations (49, 50). This 
makes it very complicated, if not impossible, to find a certain universal conversion factor between 
whole blood and OF drug concentrations. 
 
The aim of the study was to determine OF/B ratios for DRUID core substances in order to compare 
the analysis results of OF and whole blood samples collected in the epidemiological studies of the 
DRUID project. 
 
10.1.2 Sample collection and analysis 
 
Paired OF and whole blood samples were collected in Belgium, Finland, Italy and Norway from drivers 
involved in traffic accidents, drivers suspected of DUID and random drivers stopped at roadside. OF 
sampling was done with the StatSure SalivaSampler™ (StatSure Diagnostic Systems, Inc., Framing-
ham, MA, USA). The time difference between the collection of OF and whole blood sample was less 
than 30 minutes for all paired samples. The quantitative analysis of samples was performed with either 
liquid chromatography-tandem mass spectrometry or gas chromatography-mass spectrometry (or 
tandem mass spectrometry). All analytical methods were validated and external proficiency testing 
rounds were organised to assure the accuracy of the results. 
 
10.1.3 Data analysis 
 
OF/B ratios were calculated for each substance by dividing the OF concentration with the whole blood 
concentration, and zero OF/B ratios were excluded (i.e. cases where OF was negative and blood posi-
tive). Outlier OF/B ratios were identified by using box and whisker plots and the cases outside the 
outer fences were excluded as extreme outliers. 
 
After the exclusion of outliers, the following values were calculated for all substances: mean (with 95% 
confidence intervals) and median OF/B, standard deviation and the range of OF/B ratios. For these 
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calculations, only substances that had 3 or more cases that were positive in both matrices were in-
cluded. 
 
10.1.4 Results and discussion 
 
The calculated OF/B ratios and their descriptive statistics are presented in Table 9. For 6-AM, flunitra-
zepam, MDA, MDEA, and MDMA the number of cases for the OF/B ratio calculations was less than 6, 
thus the results of these substances should be interpreted with caution. Also, even for substances that 
had more than 6 cases the range of the OF/B ratios is very wide and the large standard deviations of 
the mean OF/B ratios imply that the determination of an accurate conversion factor is very difficult.  
 
Correlation of the concentrations between the two matrices was also studied by drawing the scatter 
plots of whole blood vs. OF concentration. Figure 10 and Figure 11 show the linear correlations for 
amphetamine and THC, respectively. As the figures show, the correlation for amphetamine is quite 
good, with R2 = 0.868, whereas there does not seem to be any correlation for THC, which has an R2
 
 of 
only 0.0003. Also, the number of cases with the other matrix negative (64%) is very high for THC. 
Other substances that have the other matrix negative in more than 50% of cases are 6-AM, cocaine, 
codeine, lorazepam, MDMA, morphine, oxazepam and zopiclone. 
 
 
Figure 10: Correlation of amphetamine concentrations between whole blood and oral fluid. 
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Figure 11: Correlation of THC concentrations between whole blood and oral fluid. 
 
10.1.4.1 
 
An example of the problem of determining which OF/B ratio to use as a ‘conversion factor’ 
If one would calculate a blood concentration for nordiazepam (that has a fairly good correlation be-
tween OF and whole blood, R2
Estimation of equivalent cut-off thresh-
olds in blood and oral fluid
 = 0.72), when the concentration in OF is 20 ng/ml, one would get a 
range of 327-418 ng/ml by using the 95% confidence intervals for mean. By dividing the OF concen-
tration with the mean OF/B the whole blood concentration would be 368 ng/ml and by using the me-
dian value it would be 420 ng/ml. The challenge of deciding which OF/B value to use in the calcula-
tions will be covered in the following section of the report, titled 
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Table 9: Calculated OF/B ratios and their descriptive statistics for each DRUID core substance and three addi-
tional substances. 
Substance N 
(total 
cases 
with 
posi-
tive 
find-
ings) 
N (oth-
er ma-
trix 
nega-
tive or 
below 
LOQ) 
N 
(OF/
B 
out-
liers*
) 
N 
(OF/
B for 
cal-
cula-
tions
) 
mean OF/B (95% 
confidence inter-
vals) 
SD 
for 
mea
n 
OF/B 
me-
dian 
OF/B 
min – 
max OF/B 
(outliers 
removed) 
6-AM 22 18 0 4 61.88 (-93.24-
217.01) 
97.4
9 
15.70 8.29-
207.9 
alprazolam 91 20 7 64 0.3499 (0.3009-
0.3988) 
0.19
59 
0.3310 0.03-1.06 
amphetamine 73 29 2 42 22.57 (16.82-
28.32) 
18.4
6 
17.95 3.27-
77.86 
ben-
zoylecgonine 
84 41 5 38 2.821 (1.833-
3.808) 
3.00
5 
1.578 0.18-
13.34 
clonazepam 52 14 5 33 0.1949 (0.1397-
0.2501) 
0.15
57 
0.1509 0.03-0.73 
cocaine 84 59 3 22 20.53 (13.34-
27.72) 
16.2
1 
17.05 1.19-
63.26 
codeine 93 48 5 40 6.959 (5.077-
8.840) 
5.88
3 
4.698 0.17-
23.85 
diazepam 81 37 5 39 0.0475 (0.0355-
0.0594) 
0.03
68 
0.0347 0.0005-
0.20 
flunitrazepam 1 0 0 1 0.1905    
lorazepam 35 22 0 13 0.1086 (0.0789-
0.1384) 
0.04
92 
0.0952 0.06-0.23 
MDA 5 2 0 3 11.22 (5.35-
17.10) 
2.36
5 
11.67 8.67-
13.33 
MDEA 0   0     
MDMA 15 11 0 4 13.56 (-1.87-
29.00) 
9.69
8 
11.96 3.58-
26.76 
methadone 16 5 1 10 2.810 (1.069-
4.550) 
2.43
3 
1.5009 0.69-7.12 
metham-
phetamine 
50 14 0 36 28.88 (21.67-
36.10) 
21.3
3 
20.68 5.61-
85.90 
morphine 75 39 2 34 9.498 (6.360-
12.637) 
8.99
5 
5.917 0.60-
36.73 
nordiazepam 117 44 4 69 0.0544 (0.0478-
0.0611) 
0.02
78 
0.0476 0.01-0.12 
oxazepam 53 31 2 20 0.1709 (0.1064-
0.2354) 
0.13
78 
0.1219 0.03-0.51 
THC 162 103 4 55 26.19 (17.18-
35.19) 
33.3
1 
14.12 0.09-
138.8 
zolpidem 26 5 1 20 0.3617 (0.2622-
0.4611) 
0.21
24 
0.2733 0.05-0.83 
zopiclone 17 10 1 6 2.519 (1.262-
3.776) 
1.19
8 
2.400 1.27-4.72 
Additional 
substances 
        
tramadol 26 4 0 22 12.93 (8.54-
17.32) 
9.91 11.08 1.40-
33.50 
7-amino-
clonazepam 
12 5 1 6 0.3124 (0.1971-
0.4278) 
0.10
99 
0.2778 0.20-0.49 
7-amino-
flunitrazepam 
2 1 0 1 0.1176    
* outliers are the cases for which the calculated OF/B ratio was an extreme outlier according to the 
box and whisker plot 
 
 
 
10.2 Conversion factors for whole blood and plasma 
 
Different DUID legislations use different matrices. In Europe, Germany uses serum, Belgium uses 
plasma and most of the other countries use whole blood (see Table 2). For this reason, whole blood 
was used as the common matrix in the epidemiological studies in DRUID.  
 
Blood is a complex mixture that contains solubilised proteins, dissolved fats, solids and suspended 
cells. Serum or plasma is traditionally used in clinical settings because blood affords advanced han-
dling in the laboratory procedures. Traditionally, pharmacokinetic studies have been performed on 
plasma or serum, while most post-mortem results are expressed in whole blood. This is because after 
death the red blood cells lyse. Hence, separation of red blood cells from post-mortem blood is usually 
not possible, and its composition may differ from a blood sample obtained from a living person. There-
fore, literature data of serum/plasma concentrations cannot be absolutely used to classify the concen-
trations determined from post-mortem blood. Moreover, the concentration and characteristics of cellu-
lar and extra cellular quantities differ from the ante mortem state. The water content and pH of a post-
mortem blood sample may also differ significantly from physiological ranges. The water content of 
post-mortem blood was observed to range from 60 to 90%. Immediately after death, there is a sharp 
decrease in pH up to 5.5, which again slowly increases during the post-mortem interval due to the 
break down of protein. Blood samples from the post-mortem examination are often haemolysed, pu-
trefied, and may be quite inhomogeneous mixtures. Blood collected at autopsy may be clotted or 
completely fluid or partly clotted and partly fluid. Large numbers of red blood cells are entrapped by 
clots, therefore toxicological analysis of such material will influence the detected level of any drug that 
is unevenly distributed between serum or plasma and cellular constituents of blood. 
 
Despite these limitations, it is useful to have conversion factors to calculate whole blood concentra-
tions to plasma concentration and vice-versa. There is some literature on the subject, but surprisingly 
few studies have been performed.  
 
Like all biological variables, these ratios are not constant, and there is some biological variation. 
Moreover, as the relative proportion of plasma and red blood cells varies, the ratio might also depend 
on the haematocrit (the percentage of blood volume that is occupied by red blood cells. It is normally 
about 45% for men and 40% for women). For some drugs, varying blood to plasma ratios have been 
observed between individuals. In patients, chlorpromazine erythrocyte concentrations tended to corre-
late with plasma concentrations, but the erythrocyte/plasma concentration ratio varied from 0.61 to 
2.00 between patients. Ratios may not only vary between drugs but may also differ between a particu-
lar drug and corresponding metabolites. The blood to plasma ratio of morphine was unaffected by 
variations in haematocrit and water content, whereas the corresponding ratios for morphine-3- and 
morphine-6-glucuronide were strongly influenced. The distribution of cannabinoids between blood and 
serum determined on specimens from living persons was within a closer range than the values ob-
tained from post-mortem samples. Applying blood to serum/plasma ratios from literature data to post-
mortem samples, it should be kept in mind that during lifetime an uneven blood to plasma ratio is 
maintained by active processes, which may decay after death. Generally, the differences observed 
between blood and plasma are considered to be of minor importance compared to the changes in 
concentration that may occur prior to sampling. (51) 
 
Many drugs, particularly the benzodiazepines, are highly bound to plasma protein, which has implica-
tions when forensic toxicology results are compared with therapeutic ranges based on analysis of 
plasma or serum. For protein-bound drugs such as diazepam, women will have a somewhat lower 
concentration in whole blood than men owing to gender-related differences in haematocrit. Likewise, 
any medical conditions that result in an abnormal red cell volume such as anaemia or polycythaemia 
also deserve consideration when the concentration of drugs are compared and contrasted between 
plasma and whole blood. The small interindividual variations in blood haematocrit have not until now 
been considered when forensic toxicology results are compared with therapeutic ranges based on 
therapeutic drug monitoring data (52). 
 
What should be considered when the concentration of a drug in whole blood is compared with the 
therapeutic range in plasma or serum and a decision made whether the person has overdosed? A 
good starting point are scientific papers reporting the maximal concentration (Cmax) after a single 
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therapeutic dose and the concentration at steady state (Css) after long-term therapy. Whenever pos-
sible, pharmacokinetic parameters should be considered in relation to age, gender, ethnicity, obesity, 
and any known liver or kidney dysfunction. External factors such as consumption of alcohol, alcohol-
induced liver disease, smoking, use of contraceptive steroids, pregnancy, and concomitant use of 
other drugs might influence Cmax or Css under some circumstances. Pharmaceutical aspects such 
as the dosage form, whether tablet, syrup, or sustained-release product, as well as route of admini-
stration can have a large impact on Cmax for the same dose of drug administered.  
 
In general, the concentration of a drug in plasma or serum is higher than in whole blood, especially for 
protein-bound drugs with some obvious exceptions such as the antimalaria drug chloroquine, which is 
preferentially concentrated in the erythrocytes. When the concentration of a drug in whole blood (fo-
rensic cases) is compared with the concentration in plasma or serum (therapeutic drug monitoring 
cases), this gives an advantage to the suspect when one has to decide whether the analytic result is 
suggestive of an overdose of the medication in question. 
 
The blood/plasma ratios for the core drugs from the literature are given in Table 10.  
 
Table 10: Blood/plasma ratios obtained from the literature. 
Drug Blood/plasma ratio Source 
Alcohol 0.83 0.74 − 0.90 
(53) 
(51) 
Amphetamine 
0.6-1.1; 1.0 
0.6 at 0.5 mg/L 
1.0 at 5.0 mg/L 
(53, 54) 
Methamphetamine 0.65 (55) 
MDMA 1.26 (56) 
MDEA No data  
MDA 1.27 (56) 
Cocaine 1.0 (51) 
Benzoylecgonine No data  
THC 0.55, 0.66 (53-55) 
11-OH-THC 0.62 (51) 
THCCOOH 0.57 − 0.58 0.45 − 0.71 
(51) 
(57) 
6-acetylmorphine No data  
Morphine  1.02 (51) 
Codeine  0.87 (51) 
Tramadol No data  
Methadone 0.75-1.0 (55) 
Diazepam 0.55-0.70 (51, 53, 55) 
Nordiazepam 0.59 (53, 55) 
Alprazolam 0.8; 0.625 (51, 53) 
Oxazepam 0.9-1.0 (51, 58) 
Flunitrazepam 0.75 (59) 
Zopiclone 1.0 (51) 
Zolpidem No data  
Trazodone 0.64  
Clonazepam 0.65 (53) 
Lorazepam No data  
GHB 1.20 (59) 
 
Based on the analysis at the University of Heidelberg for some experimental studies in DRUID, whole 
blood/serum ratios were determined for some opioids, THC, OH-THC and THC-COOH, dexampheta-
mine, risperidone and its hydroxyl metabolite, alprazolam and zopiclone. 
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Table 11: Whole blood/serum ratio based on DRUID results: minimum and maximum value, median ratio and 
ratio based on Bland and Altman calculation. 
Drug n minimum maximum median Bland & Altman 
Buprenorphine 5 0.50 0.63 0.54 0.55 (0.45-0.65) 
Norbuprenorphine  5 0.95 1.03 0.97 0.98 (0.91-1.05) 
Fentanyl 13 0.62 1.02 0.91 0.87 (0.63-1.11) 
Norfentanyl 13 1.03 1.55 1.22 1.26 (0.96-1.46) 
Hydromorphone 15 0.91 1.22 1.00 1.04 (0.87-1.20) 
Morphine 6 0.96 1.07 1.02 1.02 (0.95-1.09) 
Oxycodone 12 1.29 1.76 1.49 1.48 (1.24-1.72) 
Noroxycodone  12 1.28 2.09 1.81 1.73 (1.27-2.19) 
Tramadol 2 1.15, 1.24    
N-desmethyltramadol 2 1.21, 1.29    
O-desmethyltramadol 2 0.94, 1.40    
THC 165 0.33 0.94 0.62  
OH-THC 173 0.30 0.82 0.60  
THC-COOH 197 0.41 0.83 0.59  
Dexamphetamine 29 0.65 1.14 0.89  
Risperidone 10 0.56 0.71 0.66  
9-OH-risperidone 14 0.61 0.91 0.73  
Alprazolam 28 0.69 0.93 0.82  
Zopiclone 45 0.66 1.29 0,86  
 
10.3 Estimation of equivalent cut-off thresholds in blood and oral fluid 
 
There are large variations in the OF/B ratios for a substance between individuals (see section 10.1). 
Standard deviations in OF/B ratios of more than 50% are common. Therefore, conversion factors 
cannot be used for accurate estimation of drug concentrations in blood based on drug concentrations 
in oral fluid. 
 
In a cohort of drug users, the prevalence of drug concentrations above a given cut-off in oral fluid will 
reflect drug use in that cohort. The drug prevalence in oral fluid and blood will be equal if the cut-off 
concentrations are equivalent and if the cohorts are large. Equivalent cut-off concentrations in blood 
and oral fluid also imply that both specimens will, on average, be positive for a drug for the same 
length of time following the intake of a single drug dose.  
 
It has previously been found that approximately equivalent cut-off concentrations in blood and oral 
fluid for amphetamine and THC may be estimated by multiplying the cut-off concentration in blood 
with the average or median OF/B ratio or with the regression coefficient (60). Alternative methods are 
prevalence regression using aggregated population data, which in some cases may give more accu-
rate estimations (61) or a mathematical simulation, which is a more challenging procedure (60). The 
latter procedure is only applicable for large populations (e.g. more than 75 individuals).  
 
The aim of this study was to estimate equivalent drug cut-off concentrations in blood and oral fluid 
collected with Statsure Saliva sampler for estimating the prevalence of drug use in a cohort or popula-
tion.  
 
10.3.1 Sample collection and analysis 
 
See section 10.1.2 
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10.3.2 Procedures for estimating equivalent cut-off concentrations 
10.3.2.1 
 
Identification of outliers 
Outliers regarding OF/B ratios were identified using box and whisker plots, defining values outside the 
outer fences as outliers. 
10.3.2.2 
 
Using average or median OF/B ratios 
The formula for calculation of equivalent cut-off concentrations were: COF = CB × F, where COF = drug 
concentration in oral fluid, CB
10.3.2.3 
 = drug concentration in blood, and F = either the average or median 
OF/B ratio.  
 
Using prevalence regression  
Mathematical models describing the regression between concentration percentiles in oral fluid as a 
function of the corresponding concentration percentiles in blood were determined using paired sam-
ples being positive for the studied substance in both oral fluid and blood. The drug concentrations in 
oral fluid corresponding to selected percentiles, e.g. the 50th, 60th, 70th
10.3.2.4 
 etc., or the percentiles of each 
single subject, were plotted against the drug concentrations in blood corresponding to the same per-
centiles. The regression curve equations were determined using the “trendline” function in Microsoft 
Excel. Linear, quadratic and power functions were calculated. Linear functions were preferred if 
matching the data well. In some cases the highest or lowest percentiles were excluded to obtain bet-
ter fitting regression curves. For THC, the best fitting prevalence regression formula was obtained 
when including samples that were positive in only one specimen. More information on prevalence 
regression has been published previously (61). Prevalence regression was used only for substances 
where more than 10 paired samples were positive (above the analytical cut-off) for both blood and 
oral fluid. 
 
Comparison of estimation procedures 
Three formulae for the estimation of cut-off concentrations in oral fluid were generated based on the 
use of average OF/B ratio, median OF/B ratio and percentile regression. To determine which formulae 
fitted the original paired data best, the prevalence of samples above selected cut-off concentrations in 
blood was estimated using the formulae and compared with the actual prevalence in blood. The accu-
racies of the three procedures were calculated for the chosen cut-off concentrations in blood and for 
concentrations corresponding to 2.5 times and 5 times the analytical cut-off. For cocaine, diazepam, 
methamphetamine and nordiazepam slightly higher concentrations than the cut-off for blood were 
used for the calculations at the lowest concentration because one laboratory had used a higher cut-off 
for those analyses. The procedure with the least average percent deviation (in absolute value) from 
the actual number of subjects with drug concentrations above the cut-offs in blood was identified as 
the best one for each substance separately. 
 
For substances with OF/B ratios from less than 10 individuals, the cut-off concentration in oral fluid 
was estimated by multiplying the cut-off concentration in blood with the average OF/B ratio, except for 
6-AM where the median OF/B gave a better fit. 
 
10.3.3 Results and Discussion 
 
Less than 10 OF/B ratios were available for the following substances: 6-AM, flunitrazepam, MDA, 
MDEA, MDMA, zopiclone, 7-amino-clonazepam and 7-amino-flunitrazepam. Regression formulae for 
the remaining substances are presented in Table 12. Prevalence regression curves for benzoylecgon-
ine and THC are presented in Figure 12.  
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Figure 12: Prevalence regression curves for benzoylecgonine and THC. 
A comparison of the accuracies when using percentile regression, average and median OF/B values 
for estimation of equivalent cut-off concentrations for some drugs are presented in Table 13. Equiva-
lent cut-off concentrations in oral fluid were determined using the methods, which fitted the paired 
blood and oral fluid concentrations best, see  
Table 14. 
 
The estimated equivalent cutoff concentrations for oral fluid and blood were used for the calcula-
tions of drug prevalence (Deliverable 2.2.3) and for the odds ratio calculations (Deliverable 2.3.5). The 
DRUID project had originally chosen analytical cut-off concentrations in blood for diazepam and zolpi-
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dem of 20 ng/ml. The analytical methods employed for oral fluid had LOQs of 5 and 10 ng/ml, respec-
tively, in some of the participating laboratories. Initial calculations indicated that concentrations in oral 
fluid that were equivalent to the chosen cut-off concentrations for blood were lower than the LOQs. 
Therefore, the cut-off concentrations in blood for diazepam and zolpidem had to be increased to 140 
and 37 ng/ml, respectively, in order to obtain equivalent cut-off concentrations in oral fluid that were 
higher than the LOQs for the analytical methods used.  
 
Table 12: Percentile regression formulae for different substances 
DRUID core substance Percentile regression Slope or formula 
Alprazolam Linear 0.35 
Amphetamine Linear 22.84 
Benzoylecgonine Linear 1.891 
Clonazepam Linear 0.1744 
Cocaine Linear 17.69 
Codeine Linear y=6.5x + 29 
Diazepam Linear 0.0392 
Lorazepam Linear 0.0824 
Methadone Linear 2.164 
Methamphetamine Linear 24.87 
Morphine Linear 7.732 
Nordiazepam Linear 0.0624 
Oxazepam Linear 0.2644 
THC Power y=27.2x
Zolpidem 
1.39 
Linear 0.3067 
Tramadol Quadratic y = 0.0205x2
 
 + 8.5594x 
 
Table 13: Accuracies for cut-off concentrations in oral fluid that were equivalent to those use for blood 
for the three estimation methods. Numbers of cases and deviation (%) from 100% accuracy. 
 Substance 
(No. total & OF/B) 
Actual 
no. 
PR  AV ME Best ac-
curacy 
Alprazolam (n=91 & 64)          
 >10 ng/ml 39 31 (-21%) 31 (-21%) 31 (-21%) AV 
 >25 ng/ml 23 22 (-4%) 22 (-4%) 22 (-4%)  
 >50 ng/ml 14 15 (+7%) 15 (+7%) 15 (+7%)  
Amphetamine (n=73 & 42)          
 ≥20 ng/ml 43 37 (-14%) 37 (-14%) 39 (-9%) ME 
 ≥50 ng/ml 31 27 (-13%) 27 (-13%) 29 (-6%)  
 ≥100 ng/ml 23 19 (-17%) 19 (-17%) 23 (+0%)  
Benzoylecgonine (n=84 & 38)      
 ≥50 ng/ml 40 37 (-8%) 32 (-20%) 37 (-8%) PR 
 ≥125 ng/ml 28 28 (+0%) 21 (-25%) 29 (+4%)  
 ≥250 ng/ml 17 19 (+12%) 17 (+0%) 21 (+24%)  
Clonazepam (n=52 & 33)      
 ≥10 ng/ml 32 26 (-19%) 25 (-22%) 29 (-9%) PR 
 ≥25 ng/ml 16 16 (+0%) 15 (-6%) 19 (+19%)  
 ≥50 ng/ml 6 7 (+17%) 7 (+17%) 9 (+50%)  
Codeine (n=93 & 40)      
 ≥10 ng/ml 29 29 (+0%) 36 (+24%) 47 (+62%) PR 
 ≥25 ng/ml 17 16 (-6%) 20 (+18%) 26 (+53%)  
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 Substance 
(No. total & OF/B) 
Actual 
no. 
PR  AV ME Best ac-
curacy 
 ≥50 ng/ml 9 10 (+11%) 11 (+22%) 15 (+67%)  
Diazepam (n=81 & 39)          
 ≥26 ng/ml 52 48 (-8%) 47 (-10%) 50 (-4%) ME 
 ≥50 ng/ml 47 44 (-6%) 42 (-11%) 47 (+0%)  
 ≥100 ng/ml 35 36 (+3%) 34 (-3%) 39 (+11%)  
Morphine (n=75 & 34)      
 ≥10 ng/ml 33 32 (-3%) 30 (-9%) 35 (+6%) AV 
 ≥25 ng/ml 14 19 (+36%) 17 (+21%) 23 (+64%)  
 ≥50 ng/ml 8 12 (+50%) 9 (+13%) 14 (+75%)  
Nordiazepam (n=117 & 69)      
 ≥26 ng/ml 72 62 (-14%) 63 (-13%) 64 (-11%) AV 
 ≥50 ng/ml 64 52 (-19%) 55 (-14%) 57 (-11%)  
 ≥100 ng/ml 44 41 (-7%) 44 (+0%) 47 (+7%)  
Oxazepam (n=53 & 20)      
 ≥50 ng/ml 16 15 (-6%) 20 (+25%) 22 (+38%) PR 
 ≥150 ng/ml 9 10 (+11%) 12 (+33%) 13 (+44%)  
 ≥250 ng/ml 8 4 (-50%) 4 (-50%) 11 (+38%)  
THC (n=162 & 55)          
 ≥1 ng/ml 62 57 (-8%) 58 (-6%) 75 (+21%) PR 
 ≥2.5 ng/ml 35 34 (-3%) 40 (+14%) 51 (+46%)  
 ≥5 ng/ml 18 16 (-11%) 29 (+61%) 40 (+122%)  
   
PR = percentile regression, AV = multiplication with average OF/B, ME = multiplication with median 
OF/B. 
 
Table 14: Recommended cut-offs for DRUID core substances 
Substance Analytical cut-off concentrations 
(ng/mL) 
Equivalent cut-off concentrations for 
drug prevalence studies (ng/mL) 
 Blood Oral fluid Blood Oral fluid 
6-AM 10 5 10 161 
Alprazolam 10 1 10 3.5 
Amphetamine 20 25 20 360 
Benzoylecgonine 50 10 50 95 
Clonazepam 10 1 10 1.7 
Cocaine 10 10 10 170 
Codeine 10 20 10 94 
Diazepam 20 5 140 5.0
Flunitrazepam 
2 
2 1 5.3 1.01 
Lorazepam 
2 
10 1 10 1.1 
MDA 20 25 20 220
MDEA 
1 
20 25 20 270
MDMA 
3 
20 25 20 270
Methadone 
1 
10 20 10 22 
Methamphetamine 20 25 20 410 
Morphine 10 20 10 95 
Nordiazepam 20 1 20 1.1 
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Oxazepam 50 5 50 13 
THC 1 1 1.0 27 
Zolpidem 20 10 37 10
Zopiclone 
2 
10 10 10 25
Tramadol 
1 
50 50 50 480 
7-amino-clonazepam 10 1 10 3.1
7-amino-flunitrazepam 
1 
2 1 8.5 1.01 2 
1 data based on less than 10 individual cases 
2 recommended cut-off lower than the original DRUID cut-off in oral fluid 
3
 
 no positive cases; cut-off of MDMA used for MDEA 
It is expected that the studied cohort constitute a representative selection of drivers from Europe, and 
the results can therefore be used to compare drug prevalence in the countries that participated in the 
DRUID roadside surveys. However, the estimated equivalent cut-off concentrations were based on a 
limited number of cases. Therefore, it is expected that similar studies of larger cohorts might give 
slightly different results. 
 
The equivalent cut-off concentrations are only valid for studies using Statsure Saliva Sampler. The 
cut-off concentrations for different substances are not equivalent regarding impairment. 
 
 
10.4 The blood spot approach 
 
10.4.1 Introduction 
 
The use of dried blood spots (DBS) has already been described by Ivar Bang in 1913 for the determi-
nation of the blood glucose concentration in an animal study (62). However, it was not until the early 
sixties that Robert Guthrie published a DBS method for a neonatal screening to diagnose phenylke-
tonuria by determination of phenylalanine causing a more wide-spread use of this technology (63). 
This method was the basis for further DBS methods in newborn screening on congenital metabolic 
disorders (64-66), which are routinely performed today for over two decades. Despite of the limited 
sample size of 10-100 µL blood, analysis of DBS specimens has become feasible with the advent of 
increasingly sensitive MS technologies (67). Thus, DBS have recently established themselves as a 
valuable tool in therapeutic drug monitoring (68). As yet, the use of DBS in samples derived from driv-
ing under the influence of drug (DIUD) cases has not been considered at all; and the DRUID project 
offered a unique opportunity in this respect.  
 
Compared to whole blood and plasma samples, DBS provide many advantages concerning blood 
sampling, transport, storage, stability and risk of infections. Whereas whole blood and plasma sam-
pling has do be done only by medical personnel, DBS can be prepared using capillary blood after a 
finger or heel prick. This simple sampling can also be performed by non-medical personnel and is a 
less invasive alternative to taking of a blood sample. In addition, it is also possible in subjects with 
limited venous access, such as e.g. injecting drug users. Transport and storage of DBS samples can 
be performed in sealed envelopes with desiccant packs. Since no additional cooling is necessary, 
DBS can be sent via regular mail. Because of the absence of water, DBS make labile compounds 
such as ester type drugs less susceptible to degradation (69). Moreover, the use of DBS decreases 
the risk of infections with blood-borne viruses. It has been shown that HI-viruses are inactivated in 
blood samples on filter paper after the spots have been dried at room temperature (70).  
 
In literature, DBS methods using different sample volumes or DBS punch sizes for the determination 
of analytes have been published, first of all those that are of importance in a clinical setting (67). In 
addition to amino acids and acylcarnitines, proteins, triglycerides, steroids, bacteria, viruses and anti-
bodies can be determined (65). Sensitive LC-MS/MS techniques also allow the analyses of smaller 
molecules like non-protein drug substances (67). Besides LC-MS/MS, radioimmunoassay or GC-MS 
were used for DBS analysis (69, 71).  
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With respect to all these advantages, DBS have been considered to be a suitable sample material for 
drug analysis in DUID cases. Since blood sampling can be performed by non-medical personnel it is 
not necessary to wait for the doctor. Roadside sampling is considered to be most advantageous re-
flecting the actual blood concentration and hence impairment at the time of the police stop or at the 
scene. This will obviate the need for a re-estimation of the analytical result back to this point of time 
which is regularly imprecise if possible at all. Therefore, the major objective of the investigation was to 
test whether DBS results are comparable to the concentrations determined from whole blood speci-
mens being a major prerequisite for the basic application of DBS analysis. The following paragraph 
presents the results of DBS analysis of d-amphetamine (n=29), 3,4-methylenedioxy-
methamphetamine (MDMA, n=75, 38 of placebo condition, 37 of active treatment), morphine (n=7), 
hydromorphone (n=16), fentanyl (n=13), oxycodone (n=12), risperidone (n=15), alprazolam (n=33) 
and zopiclone (n=90, 45 of each placebo or active treatment condition) in authentic samples and their 
comparison with the results of the determination from corresponding whole blood samples. In case of 
MDMA, fentanyl, oxycodone, risperidone and alprazolam, determination of major or active metabolites 
was included. 
 
10.4.2 Materials and methods 
 
A customised collection device for use in the sampling study has been prepared by GE Healthcare 
(Figure 1, GE Healthcare, Dassel, Germany) from #903 Whatman specimen collection paper which is 
manufactured from 100% pure cotton linters with no wet-strength additives.  
  
Figure 13: Blood spot card, face and back of the card 
 
This paper is a FDA class II medical device complying with FDA regulations during manufacture. In 
addition, the post-printing quality of the cards had been checked testing a random sampling of forms 
from this particular batch for blood absorption time, circle size and caliper. Four preprinted circles 
were available with dotted line circles on one side of the paper (16 mm internal diameter). Information 
that should be provided at the face of card was: shipper’s account number, name of the participant 
(anonymous), address, postcode, phone and email. On the back of the card, a detailed instruction is 
given how the sample should be applied. In addition, all co-operating partners were instructed on the 
proper method for collecting DBS samples on at least 2 occasions. DBS were dried folding the card 
along the line where the 2 papers are stacked together at ambient temperature for 3 hours; then, they 
were stored in a zip lock bag containing a desiccant pad until shipped by regular mail as a diagnostic 
specimen. Matching whole blood samples where stored at -20°C until shipped on dry ice.  
 
10.4.3 Extraction and quantitative determination 
 
DBS had been prepared by spotting a 100 µL aliquot of whole blood onto the custom made DRUID 
card. For some of the analytes, analytical assays have been developed while for some others, hith-
erto existing assays have been modified and downscaled to a sample volume of 100 µL. From both, 
DBS and 100 µL of whole blood the following analytes have been determined: MDMA, 
3,4-methylenedioxyamphetamine (MDA), d-amphetamine morphine, hydromorphone, fentanyl, nor-
fentanyl, oxycodone, noroxycodone, risperidone, 9-hydroxy-risperidone (9-OH-risperidone), alpra-
zolam, hydroxyalprazolam and zopiclone. Before extraction, DBS were completely cut out and trans-
ferred into plastic tubes. Analysis was performed by liquid chromatography/tandem mass spectrome-
try (LC/MS/MS) following liquid/liquid extraction. Only hydromorphone was isolated by solid phase 
extraction. Each sample was extracted twice; deuterated internal standards were used as far as 
available.  
 
Table 15 gives an overview on the extraction procedures and mass spectrometry conditions devel-
oped for the different analytes. 
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Calibration lines were prepared separately for either whole blood or blood spots and assessed for 
linearity using by least squares regression using the ratio of the target analyte peak area to the corre-
sponding internal standard peak area. 
  
10.4.4 Validation 
 
Imprecision, extraction efficiency and bench top stability (24 h) were investigated according to the 
FDA Guidance for Industry (72). Carryover was checked as described by Bansal and DeStefano (73). 
Ion suppression or enhancement was determined according to Matuszewski et al. (74). The lower 
limit of detection (LLOD) and quantitation (LLOQ) was estimated from the calibration curves according 
to DIN 32465 at a probability of 95% (75). 
 
Data analysis was done using Microsoft Excel®. Agreement of the whole blood and DBS concentra-
tions was further assessed by a Bland-Altman plot (76), which is a method commonly used in clinical 
chemistry to compare two measurement techniques. The differences between the concentrations of 
matching pairs are plotted against the averages of the two methods. Horizontal lines are drawn at the 
mean difference, and at the limits of agreement, which are defined as the mean difference plus and 
minus the 1.96-fold standard deviation SD of the differences. Agreement between two assays exists if 
95% of the values lie within these limits.  
 
10.4.5 Materials and instrumentation 
 
Zopiclone was purchased from Rhône Poulenc Rorer (Cologne, Germany). Risperidone, 
9-OH-risperidone and didehydromethylrisperidone (internal standard) were supplied by Janssen-Cilag 
(Neuss, Germany). Amphetamine, MDMA, MDA, morphine, hydromorphone, fentanyl, norfentanyl, 
oxycodone, noroxycodone, alprazolam and hydroxyalprazolam as well as their deuterated standards 
and lorazepam-d4
 
 were obtained from LGC, Wesel, Germany. High-pressure liquid chromatography 
(HPLC)-grade acetonitrile and methanol as well as ethyl acetate (≥  99.5%), toluene (≥  99.5%), iso-
propanol (≥ 99.5%), solid NaOH (≥  99%), ammonium acetate (≥ 98%), acetic acid (100%) were from 
Roth (Karlsruhe, Germany). Isoamyl alcohol (≥ 99%), dichloromethane (≥ 99.8%), ammonium hydrox-
ide (25%), hydrochloric acid (25%), sodium carbonate (≥  99.5%), sodium hydrogen carbonate (≥  
99.5%), potassium chloride (≥  99.5%) und boric acid (≥  99.8%) were supplied by Merck (Darmstadt, 
Germany). Double distilled water was obtained from Braun (Melsungen, Germany). Drug-free whole 
blood for preparation of calibration lines and validation standards were purchased from the local blood 
bank of the University Hospital of Heidelberg. For solid phase extraction of hydromorphone, Bond-Elut 
C8 1 mL columns were used (Varian, Darmstadt, Germany). 
LC-MS/MS analysis was performed on an API 4000 tandem MS with a TurboIon ionization source 
operated in the positive-ion mode (AB Sciex, Darmstadt, Germany). It was interfaced to an HPLC 
pump equipped with an autosampler 1100 series, Agilent, Waldbronn, Germany).  
 
Table 15: Analysis of d-amphetamine, MDMA, MDA, morphine, hydromorphone, fentanyl, norfentanyl, 
oxycodone, noroxycodone, risperidone, 9-OH-risperidone, alprazolam and zopiclone: extraction, 
chromatography and mass spectrometry conditions 
 
analyte adjust-
ment of 
the pH-
value for 
extrac-
tion 
internal 
standard (IS) 
extracting 
agent 
[vol%] 
mobile 
phase 
A:B:CΔ[v:
v:v] 
flow 
[µL/mi
n] 
reten-
tion 
time 
[min] 
co
lu
m
n 
transition 
used for 
quantita-
tion 
transi-
tion 
IS 
MDMA
MDA
1 
d-
ampheta-
mine
1 
0.01 M 
NaOH 
1 
MDMA-d
MDA-d
5 
amphetami-
ne-d
5 
ethyl acetate 
5 
60:8:32 220 2,15 
2,08 
1.71 
♦ 194163 
180163 
13691 
199165 
180135 
141124 
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analyte adjust-
ment of 
the pH-
value for 
extrac-
tion 
internal 
standard (IS) 
extracting 
agent 
[vol%] 
mobile 
phase 
A:B:CΔ[v:
v:v] 
flow 
[µL/mi
n] 
reten-
tion 
time 
[min] 
co
lu
m
n 
transition 
used for 
quantita-
tion 
transi-
tion 
IS 
morphine borate 
buffer 
pH 8.5 
2 morphine-d3 ethyl acetate   50:10:40 220 2.00 ♦ 286152 289152 
hydromor-
phone
carbonate 
buffer 
pH 9.0 
3 
hydromor-
phone-d3
 
  
dichloro-
methane/ 
isopropanol/ 
conc. NH3
50:10:40 
 
80:20:2  
300 1.18 # 286185 289185 
fentanyl 
norfentanyl 
5%NH fentanyl-d3 5
norfentanyl-d
  ethyl acetate 
5
 
40:12:48 250 1.69 
1.36 
# 337188 
23384 
342188 
23884 
oxycodone 
noroxy-
codone 
5%NH oxycodone-d3 6
norxy-
codone-d
  
6
ethyl acetate 
  
50:10:40 300 1.20 
1.11 
# 316298 
302284 
322304 
305287 
risperidone 
9-OH-
risperidone 
borate 
buffer 
pH 8.5 
didehydro-
methyl- 
risperidone  
ethyl acetate 50:10:40 300 2.00 
1.90 
# 411191 
427207 
421201 
alprazolam 
hydroxyal-
prazolam 
borate 
buffer 
pH 8.5 
alprazolam-d tolu-
ene/isoamyl 
alcohol 95:5  
5 45:11:44 250 3.70 
2.99 
# 309205 
325297 
314210 
330302 
zopiclone borate 
buffer 
pH 8.5 
lorazepam-d tolu-
ene/isoamyl 
alcohol 95:5  
4 40:12:48 300 1.15 # 389245 325307 
Δ 
# Phenomenex Luna C
A: 4 mM ammonium acetate buffer pH 3,2; B: methanol; C: acetonitrile 
18
♦ Agilent Zorbax Eclipse XDB-C
 2,0 mm x 150 mm, particle size 5 µm, Phenomenex, Aschaffenburg, Germany 
8
 
 2,1 mm x 150 mm. particle size 5 µm, Agilent, Waldbronn, Germany 
1 the organic phase was acidified with 50 µL of methanol HCl (49:1, v:v) prior to evaporation to dryness 
2 ultrasonication (5 min) was applied following addition of borate buffer and IS 
3
10.4.6 Results and discussion 
 solid phase extraction 
 
10.4.6.1 
 
Evaluation 
Table 16 gives an overview on the validation results determined in DBS. Additionally, matrix effect, 
extraction efficiency and 24 h bench top stability were checked; all values were within acceptable 
ranges (data not shown). It could also be observed that matrix effects in DBS are of a lesser extent 
than in whole blood (data not shown). Matrix effects exerting a serious impact on the results are gen-
erally considered as a major drawback of LC-MS/MS analysis. Carryover could not be observed for 
any analyte. There were no significant differences between the validation results in blood and DBS; all 
parameters were in the same range as presented in Table 16 or better.  
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Table 16: Validation results for the most important substances determined in plasma 
analyte LLOD 
[ng/mL] 
LLOQ 
[ng/mL] 
between-run precision 
[%] 
within-run precision 
[%] 
linearity 
amphetamine 0.7 2.6 12 ng/mL: 3.9 
40 ng/mL: 5.2 
12 ng/mL: 2.6 
40 ng/mL: 3.3 
5-40 ng/mL 
r=0.9999 
MDMA 
 
0.4 1.4 20 ng/mL: 4.9 
250 ng/mL: 7.8 
20 ng/mL: 3.6 
250 ng/mL: 3.6 
A: 50-
400 ng/mL 
r=1.0000 
B: 5-40 ng/mL 
r=0.9997 
MDA 0.1 0.5 5 ng/mL:  4.6 
15 ng/mL: 6.6 
5 ng/mL:  3.8 
15 ng/mL: 5.0 
A: 5-40 ng/mL 
r=0.9999 
B: 0.5-4 ng/mL 
r=0.9999 
morphine 1.3 4.8 250 ng/mL: 5.6 250 ng/mL: 5.6 50-500 ng/mL 
r=1.0000 
hydromorphone 0.4 1.4 4 ng/mL:  3.4 
12 ng/mL: 3.6 
4 ng/mL:  1.8 
12 ng/mL: 1.4 
2-20 ng/mL 
r=1.0000 
fentanyl 0.02 0.08 0.25 ng/mL: 4.0 
6.5 ng/mL: 4.1 
0.25 ng/mL: 3.3 
6.5 ng/mL: 2.4 
0.1-10 ng/mL 
r=1.0000 
norfentanyl 0.02 0.08 0.25 ng/mL: 4.9 
2.0 ng/mL: 3.8 
0.25 ng/mL: 1.1 
2.0 ng/mL: 2.0 
0.1-4.0 ng/mL 
r=1.0000 
oxycodone 0.1 0.3 10 ng/mL: 6.7 
100 ng/mL: 3.6 
10 ng/mL: 2.7 
100 ng/mL: 3.6 
5-100 ng/mL 
r=1.0000 
noroxycodone 0.1 0.4 10 ng/mL: 5.7 
80 ng/mL: 3.1 
10 ng/mL: 5.2 
80 ng/mL: 2.5 
5-100 ng/mL 
r=0.9989 
risperidone 0.3 1.2 6.7 ng/mL: 3.1 
19.75 ng/mL: 3.9 
6.7 ng/mL: 2.6 
19.75 ng/mL: 3.9 
5-25 ng/mL 
r=0.9997 
9-OH-
risperidone 
0.3 1.3 10 ng/mL: 3.7 
40 ng/mL: 5.8 
10 ng/mL: 2.1 
40 ng/mL: 4.9 
5-60 ng/mL 
r=0.9999 
alprazolam 0.2 0.7 5 ng/mL:  7.2 
30 ng/mL: 5.2 
5 ng/mL:  5.3 
30 ng/mL: 4.0 
2.5-50 ng/mL 
r=0.9999 
zopiclone 0.1 0.3 10 ng/mL: 6.0 
50 ng/mL: 4.2 
10 ng/mL: 2.5 
50 ng/mL: 2.0 
10-50 ng/mL 
r=0.9999 
10.4.6.2  
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10.4.6.3 
 
Concentrations of analytes determined from DBS and comparison of the results with those 
of whole blood 
All results > LLOQ of DBS analysis are summarised in Table 17. 
 
 
Table 17: Results of DBS analysis obtained from authentic samples 
analyte n>LLOQ concentration  
range [ng/mL] 
mean 
[ng/mL] 
median 
[ng/mL] 
d-amphetamine 29 10.9-43.9 21.6 20.4 
MDMA 36 2.5-447.5 181.3 172.7 
MDA 32 0.9-24.1 8.9 8.6 
morphine  7 82.2-472.6 238.1 209.2 
hydromorphone 15 2.4-19.3 8.7 7.6 
fentanyl 13 0.18-6.27 1.26 0.49 
norfentanyl 13 0.07-2.28 0.47 0.21 
oxycodone 12 19.3-123.6 61.2 57.1 
noroxycodone 12 20.4-86.5 42.6 33.8 
risperidone 11 1.2-20.8 9.5 6.2 
9-OH-risperidone 14 4.2-30.8 14.7 14.7 
alprazolam 28 2.5-20.1 6.2 5.2 
zopiclone 45 9.7-39.8 22.1 21.5 
 
With respect to the advantages mentioned in the introduction, DBS may be a suitable method for 
roadside blood sampling in case of suspected DUID. Before DBS can be used for drug testing, it must 
be shown that DBS analysis is able to provide results that are as reliable as those using whole blood 
samples. Therefore, blood and matching DBS specimens were provided for all drugs investigated 
during the particular DRUID studies in Germany, Italy, Greece and The Netherlands. Results of both 
media were compared using the DBS/blood ratio (DBS/b) and Bland-Altman analysis. Accordingly, 
the respective mean of the corresponding results determined with the two different methods were 
plotted on the x-axis and their difference on the y-axis. In contrast to a scatter plot of blood and corre-
sponding DBS concentrations, the Bland-Altman difference plot allows to assess the distribution of the 
differences over the whole concentration range. The mean of the differences indicates an over- or 
underestimation by one of the two methods. Besides the mean of the differences, the 95% limits of 
agreement were calculated as the mean difference ±1.96 • SD. In case of a normal distribution, 95% 
of the differences are expected to lie within these limits (76). Ideally, the mean DBS/b ratio should be 
equal to 1.00, which means that results from whole blood and DBS analysis do not differ. 
 
Table 20 in the appendix provides information on the results of the analysis of the investigated drugs 
in whole blood. Hydroxyalprazolam could be detected either at a concentration < LLOQ or not at all 
due to the short time between drug administration and collection of the blood specimens. Therefore, 
this analyte has not been considered further. All analytes and their corresponding DBS/b ratios includ-
ing respective RSD are summarised in Table 18. 
 
 
Table 18: Summary of DBS/b ratios and RSDs 
analyte n DBS/b 
range 
DBS/b 
mean 
RSD 
[%] 
d-amphetamine 29 0.94-1.15 1.05  5.23 
MDMA 36 0.92-1.09 1.01  2.89 
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analyte n DBS/b 
range 
DBS/b 
mean 
RSD 
[%] 
MDA 32 0.85-1.26 1.03  6.44 
morphine  7 0.95-1.02 0.99  2.22 
hydromorphone 15 0.86-1.08 0.99  6.36 
fentanyl 13 0.90-1.09 1.00  8.56 
norfentanyl 13 0.84-1.05 0.97  5.94 
oxycodone 12 0.98-1.10 1.02  3.52 
noroxycodone 12 0.89-1.06 1.00  4.32 
risperidone 10 0.86-0.97 0.93  3.51 
9-OH-risperidone 14 0.91-1.03 0.97  4.56 
alprazolam 28 0.92-1.25 1.03  6.79 
zopiclone 45 0.63-1.22 0.86 15.86 
 
For all samples containing opioid type drugs the estimated DBS/b ratios were in an acceptable range 
and showed a small range of variation. Also, ratios and RSDs for the benzodiazepine-type drug alpra-
zolam as well as for amphetamine derivatives such as MDMA, MDA and d-amphetamine indicate that 
methods for blood and DBS determination do not differ.  
 
As an example, MDMA could be quantified in DBS as reliably as in whole blood specimens which was 
already evident from the DRUID deliverable of July 2010 (77). The results obtained in the current 
study confirmed once again equality of both methods. In addition, equivalence of the methods could 
be proven for MDA, which is a minor but active metabolite of MDMA: The DBS/b ratio of 1.03 is very 
close to 1.00; a very low coefficient of variation of 6.44% and a very small mean difference between 
both methods could be estimated from the results. Figure 14 shows the Bland-Altman difference plot 
obtained for MDA in DBS and whole blood: 
MDA: Bland-Altman-Plot
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Figure 14: Bland-Altman difference plot for MDA. The solid line illustrates the mean difference of 0.02 ng/mL, the 
dotted lines indicate the limits of agreement set to 1.96 • SD (-1.36 and 1.40 ng/mL). 
All values except for a single one are within the limits of agreement. No trend of the differences be-
tween the results obtained from either blood or DBS values over the whole concentration range could 
be observed. Especially, the very small mean difference leaves no doubt that analysis of MDA from 
DBS is as reliable as from whole blood. This conclusion could also be drawn from the Bland-Altman 
analysis of all other analytes under investigation except zopiclone. No trend of the differences over 
the concentration range could be observed for any of the substances under investigation. Additionally, 
the number of outliers was always below 5%. Also, DBS/b ratios were very close to 1.00. 
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Contrary, the DBS/b ratio of zopiclone being 0.86 indicates an overestimation of the results from 
blood compared to DBS. This overestimation is supported by the mean difference calculated for the 
Bland-Altman difference plot of zopiclone (Figure 15). 
 
zopiclone: Bland-Altman difference plot
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Figure 15: Bland-Altman difference plot for zopiclone. The solid line illustrates the mean difference of 3.99 ng/mL, 
the dotted lines indicate the limits of agreement set to 1.96 • SD (-3.62 and 11.59 ng/mL). 
Whole blood samples were stored at -20°C until analysis, whereas DBS were kept at ambient tem-
perature. With respect to the different temperatures of storage, degradation of zopiclone to 2-amino-5-
chloropyridine might have occurred which has recently been published for whole blood samples by 
Nilsson et al. (78). Currently, a stability investigation is in process to compare the degradation in 
whole blood and DBS at the same storage conditions. Results may enable a conclusion concerning 
the best storage conditions and whether determination from DBS is superior to that of whole blood. 
 
In addition to the DBS/b ratios presented in Table 18, Table 19 gives the results of the Bland-Altman 
analyses for all analytes. Concentrations determined from corresponding whole blood samples are 
summarised in Table 20. 
 
Table 19: Summary of results of the Bland-Altman difference plots. 
#: the lowest DBS concentration of risperidone was not considered for Bland-Altman analysis, due to the fact that 
the corresponding blood concentration was below the LLOQ of whole blood analysis. 
analyte mean difference 
blood-DBS 
[ng/mL] 
mean-1.96xSD 
[ng/mL] 
mean +1.96xSD  
[ng/mL] 
mean difference/mean  
blood concentration 
[%] 
d-amphetamine -1.03  -3.32  1.25 -5.01 
MDMA  3.55 -14.34  7.25 -1.94 
MDA  0.01  -1.33  1.35  0.09 
morphine  2.12  -8.30 12.53  0.88 
hydromorphone  0.14  -0.90  1.17  1.53 
fentanyl -0.02  -0.19  0.15 -1.76 
norfentanyl  -0.006  -0.068  0.055 -1.34 
oxycodone -1.24  -4.46  1.98 -2.07 
noroxycodone  0.27  -3.26  3.80  0.63 
risperidone#  0.83  -0.67  2.32  7.44 
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9-OH-
risperidone 
 0.64  -1.13  2.40  4.15 
alprazolam -0.11  -1.01  0.80 -1.81 
zopiclone  3.99  -3.62 11.59 15.30 
 
Obviously, for no analyte except zopiclone the mean difference exceeded ±10% of the mean blood 
concentration. Therefore, DBS and whole blood methods for the analytes investigated during the 
DRUID project can be regarded to be equivalent. 
 
10.4.6.4 
 
Conclusions 
The DBS assay has potential as a precise and inexpensive option for the determination of several 
analytes in small blood samples. The small sample volume of 100 µL requires very sensitive tech-
niques. By using LC-MS/MS, all analytes investigated in the presented study could be determined 
with sufficient LLOQs. Evaluation data showed no significant differences in precision as well as 
LLODs and LLOQs. Analysis of DBS is feasible with the advent of increasingly sensitive MS tech-
nologies such as LC-MS/MS. Although optimization of extraction procedures is necessary, DBS 
analysis turned out to be superior to determination from whole blood with regard to matrix effects.  
 
The DBS/b ratios were very close to 1.00, and the relative standard deviations ≤ 8.56%. Measures of 
under-/overestimation were readily provided by Bland-Altman difference plots, and 95% of all differ-
ences between the concentrations determined from either whole blood or DBS were within the limits 
of agreement. Also, differences were uniformly distributed across the concentration ranges. Except 
zopiclone, which is very sensitive to degradation, all substances investigated in the presented studies 
could be determined in DBS as reliably as in whole blood specimens. A zopiclone stability study in 
blood and DBS samples is running to compare the extent of degradation in both media: then, conclu-
sions can be drawn concerning the optimum sample material and optimum temperature for storage. 
 
The use of DBS in routine analysis will result in simplified handling during blood sampling, transport 
and storage as well as sample processing in the laboratory. The present device had well character-
ised properties with regard to blood volume/unit area and chromatography. Considering that the blood 
spot size depends on the hematocrit value for analytes whose distribution between blood and plasma 
differs from one, extraction of the whole DBS is recommended (79).  
 
Based on the present results, DBS drug analysis can be regarded as a valuable and inexpensive 
alternative to determination from whole blood. We are quite confident that the use of DBS will facilitate 
blood analysis in DUID cases in the near future. 
 
10.4.6.5 
 
Appendix 
Table 20: Summary of the results obtained from whole blood. 
analyte range[ng/mL] mean [ng/mL] median [ng/mL] 
d-amphetamine 10.8-40.7 20.6 19.6 
MDMA 2.8-444.3 177.9 171.0 
MDA 0.86-24.4 8.9 9.0 
morphine 82.4-479.1 240.2 215.7 
hydromorphone 2.3-20.2 8.8 7.0 
fentanyl 0.18-6.10 1.24 0.52 
norfentanyl 0.08-2.21 0.46 0.21 
oxycodone 17.8-122.6 59.9 53.7 
noroxycodone 20.6-91.2 42.9 33.6 
risperidone 4.3-22.7 11.1 6.6 
9-OH-risperidone 4.1-29.8 15.3 15.5 
alprazolam 2.1-20.7 6.0 5.2 
zopiclone 10.1-49.1 26.1 24.9 
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